



HEALTH ANNUAL STATEMENT

AS OF DECEMBER 31, 2023
OF THE CONDITION AND AFFAIRS OF THE

Aetna Health Inc. (a New Jersey corporation)

NAIC Group Code 0001 0001 NAIC Company Code 95287 Employer's ID Number 52-1270921
(Current) (Prior)

Organized under the Laws of New Jersey State of Domicile or Port of Entry NJ

Country of Domicile United States of America

Licensed as business type: Health Maintenance Organization

Is HMO Federally Qualified? Yes [] No [X]

Incorporated/Organized 05/18/1982 Commenced Business 03/01/1983

Statutory Home Office 9 Entin Road, Suite 203 Parsippany, NJ, US 07054
(Street and Number) (City or Town, State, Country and Zip Code)

Main Administrative Office 1425 Union Meeting Road
(Street and Number)
Blue Bell, PA, US 19422 800-872-3862
(City or Town, State, Country and Zip Code) (Area Code) (Telephone Number)

Mail Address Attn: Stat Compliance; P.O. Box 818048 Cleveland, OH, US 44181-8048
(Street and Number or P.O. Box) (City or Town, State, Country and Zip Code)

Primary Location of Books and Records 9 Entin Road, Suite 203
(Street and Number)
Parsippany, NJ, US 07054 973-244-3500
(City or Town, State, Country and Zip Code) (Area Code) (Telephone Number)

Internet Website Address www.aetna.com

Statutory Statement Contact Kim E. Roth 215-775-6508
(Name) (Area Code) (Telephone Number)
StatutoryReporting@aetna.com 860-262-7767
(E-mail Address) (FAX Number)

OFFICERS

President Jason Henry Tompkins Vice President and Secretary Edward Chung-I Lee

OTHER

Derek Scott Blunt, Senior Investment Officer Steven Matthew Conte, Principal Financial Officer and Controller Peter Keller, Assistant Controller
Tracy Louise Smith, Vice President and Treasurer Whitney Dorothy Todisco, Assistant Controller

DIRECTORS OR TRUSTEES

Ellen Dworkin Anderson Jason Henry Tompkins

The officers of this reporting entity being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC Annual Statement Instructions and Accounting Practices and Procedures manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

Jason Henry Tompkins
 President

Edward Chung-I Lee
 Vice President and Secretary

State of..... Pennsylvania
 County of..... Montgomery


Subscribed and sworn to before me this
30th day of January, 2024

NOTARY PUBLIC (Seal)

State of..... Connecticut
 County of..... Hartford

Subscribed and sworn to before me this
6 day of February, 2024

NOTARY PUBLIC (Seal)



KATRINA COFFEY
NOTARY PUBLIC
 My Commission Expires Feb. 28, 2027

- a. Is this an original filing? Yes [X] No []
 b. If no,
 1. State the amendment number.....
 2. Date filed
 3. Number of pages attached.....

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

ASSETS

	Current Year			Prior Year
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1. Bonds (Schedule D)	210,712,721	0	210,712,721	206,047,848
2. Stocks (Schedule D):				
2.1 Preferred stocks	0	0	0	0
2.2 Common stocks	0	0	0	0
3. Mortgage loans on real estate (Schedule B):				
3.1 First liens	0	0	0	0
3.2 Other than first liens	0	0	0	0
4. Real estate (Schedule A):				
4.1 Properties occupied by the company (less \$0 encumbrances)	0	0	0	0
4.2 Properties held for the production of income (less \$0 encumbrances)	0	0	0	0
4.3 Properties held for sale (less \$0 encumbrances)	0	0	0	0
5. Cash (\$1,006,281, Schedule E - Part 1), cash equivalents (\$3,774,973, Schedule E - Part 2) and short-term investments (\$0, Schedule DA)	4,781,254	0	4,781,254	9,869,090
6. Contract loans, (including \$0 premium notes)	0	0	0	0
7. Derivatives (Schedule DB)	0	0	0	0
8. Other invested assets (Schedule BA)	0	0	0	0
9. Receivables for securities	8,750	0	8,750	8,750
10. Securities lending reinvested collateral assets (Schedule DL)	0	0	0	0
11. Aggregate write-ins for invested assets	0	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	215,502,725	0	215,502,725	215,925,688
13. Title plants less \$0 charged off (for Title insurers only)	0	0	0	0
14. Investment income due and accrued	1,978,531	0	1,978,531	1,922,479
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection	1,907,208	603,488	1,303,720	1,483,737
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$0 earned but unbilled premiums)	0	0	0	0
15.3 Accrued retrospective premiums (\$1,265,999) and contracts subject to redetermination (\$22,337,057)	23,603,056	0	23,603,056	15,082,383
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers	0	0	0	0
16.2 Funds held by or deposited with reinsured companies	2,279,876	2,279,876	0	0
16.3 Other amounts receivable under reinsurance contracts	0	0	0	0
17. Amounts receivable relating to uninsured plans	2,988,150	0	2,988,150	1,541,726
18.1 Current federal and foreign income tax recoverable and interest thereon	1,463,693	0	1,463,693	0
18.2 Net deferred tax asset	933,408	0	933,408	421,316
19. Guaranty funds receivable or on deposit	0	0	0	0
20. Electronic data processing equipment and software	0	0	0	0
21. Furniture and equipment, including health care delivery assets (\$0)	0	0	0	0
22. Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0	0
23. Receivables from parent, subsidiaries and affiliates	0	0	0	0
24. Health care (\$2,799,544) and other amounts receivable	3,384,007	584,463	2,799,544	2,957,087
25. Aggregate write-ins for other than invested assets	231,382	0	231,382	0
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	254,272,036	3,467,827	250,804,209	239,334,416
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
28. Total (Lines 26 and 27)	254,272,036	3,467,827	250,804,209	239,334,416
DETAILS OF WRITE-INS				
1101.				
1102.				
1103.				
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501. State income tax receivable	231,382	0	231,382	0
2502.				
2503.				
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	231,382	0	231,382	0

LIABILITIES, CAPITAL AND SURPLUS

	Current Year			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
1. Claims unpaid (less \$ 1,317,166 reinsurance ceded)	42,679,928	2,417,457	45,097,385	49,773,044
2. Accrued medical incentive pool and bonus amounts	7,756,391	0	7,756,391	7,013,149
3. Unpaid claims adjustment expenses.....	772,776	0	772,776	979,316
4. Aggregate health policy reserves, including the liability of \$ 1,361,792 for medical loss ratio rebate per the Public Health Service Act	32,784,341	0	32,784,341	24,395,218
5. Aggregate life policy reserves.....	0	0	0	0
6. Property/casualty unearned premium reserves.....	0	0	0	0
7. Aggregate health claim reserves.....	24,975	0	24,975	18,227
8. Premiums received in advance.....	1,659,164	0	1,659,164	668,168
9. General expenses due or accrued.....	639,111	0	639,111	1,378,369
10.1 Current federal and foreign income tax payable and interest thereon (including \$0 on realized capital gains (losses))	0	0	0	13,714
10.2 Net deferred tax liability.....	0	0	0	0
11. Ceded reinsurance premiums payable.....	0	0	0	0
12. Amounts withheld or retained for the account of others.....	17,447	0	17,447	18,627
13. Remittances and items not allocated.....	505,330	0	505,330	551,068
14. Borrowed money (including \$0 current) and interest thereon \$0 (including \$0 current).....	0	0	0	0
15. Amounts due to parent, subsidiaries and affiliates.....	8,191,665	0	8,191,665	9,247,146
16. Derivatives.....	0	0	0	0
17. Payable for securities.....	1,006,281	0	1,006,281	0
18. Payable for securities lending	0	0	0	0
19. Funds held under reinsurance treaties (with \$0 authorized reinsurers, \$ 413,000 unauthorized reinsurers and \$0 certified reinsurers).....	412,970	0	412,970	631,737
20. Reinsurance in unauthorized and certified (\$0) companies	3,184,072	0	3,184,072	2,346,030
21. Net adjustments in assets and liabilities due to foreign exchange rates	0	0	0	0
22. Liability for amounts held under uninsured plans.....	1,557,848	0	1,557,848	3,169,423
23. Aggregate write-ins for other liabilities (including \$0 current).....	0	0	0	0
24. Total liabilities (Lines 1 to 23).....	101,192,299	2,417,457	103,609,756	100,203,236
25. Aggregate write-ins for special surplus funds.....	XXX	XXX	0	0
26. Common capital stock.....	XXX	XXX	200	200
27. Preferred capital stock.....	XXX	XXX	0	0
28. Gross paid in and contributed surplus.....	XXX	XXX	68,731,093	68,731,093
29. Surplus notes.....	XXX	XXX	0	0
30. Aggregate write-ins for other than special surplus funds.....	XXX	XXX	0	0
31. Unassigned funds (surplus).....	XXX	XXX	78,463,160	70,399,887
32. Less treasury stock, at cost:				
32.10 shares common (value included in Line 26 \$0).....	XXX	XXX	0	0
32.20 shares preferred (value included in Line 27 \$0).....	XXX	XXX	0	0
33. Total capital and surplus (Lines 25 to 31 minus Line 32).....	XXX	XXX	147,194,453	139,131,180
34. Total liabilities, capital and surplus (Lines 24 and 33).....	XXX	XXX	250,804,209	239,334,416
DETAILS OF WRITE-INS				
2301.				
2302.				
2303.				
2398. Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399. Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	0	0	0	0
2501.	XXX	XXX		
2502.	XXX	XXX		
2503.	XXX	XXX		
2598. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3001.	XXX	XXX		
3002.	XXX	XXX		
3003.	XXX	XXX		
3098. Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099. Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	Current Year		Prior Year
	1 Uncovered	2 Total	3 Total
1. Member Months.....	XXX	400,793	475,116
2. Net premium income (including \$0 non-health premium income)	XXX	511,246,083	527,855,573
3. Change in unearned premium reserves and reserve for rate credits	XXX	(515,842)	633,749
4. Fee-for-service (net of \$0 medical expenses)	XXX	0	0
5. Risk revenue	XXX	0	0
6. Aggregate write-ins for other health care related revenues	XXX	0	0
7. Aggregate write-ins for other non-health revenues	XXX	0	0
8. Total revenues (Lines 2 to 7)	XXX	510,730,241	528,489,322
Hospital and Medical:			
9. Hospital/medical benefits	18,459,134	323,318,009	353,440,270
10. Other professional services	1,200,320	21,024,020	21,356,577
11. Outside referrals	8,305,966	8,305,966	9,176,737
12. Emergency room and out-of-area	968,169	16,957,812	19,732,750
13. Prescription drugs	0	58,311,624	59,119,905
14. Aggregate write-ins for other hospital and medical.....	0	0	0
15. Incentive pool, withhold adjustments and bonus amounts	0	10,099,866	8,672,557
16. Subtotal (Lines 9 to 15)	28,933,589	438,017,297	471,498,796
Less:			
17. Net reinsurance recoveries	0	14,987,543	15,279,417
18. Total hospital and medical (Lines 16 minus 17)	28,933,589	423,029,754	456,219,379
19. Non-health claims (net)	0	0	0
20. Claims adjustment expenses, including \$9,166,106 cost containment expenses	0	13,189,207	10,319,044
21. General administrative expenses	0	56,977,367	55,505,102
22. Increase in reserves for life and accident and health contracts (including \$0 increase in reserves for life only)	0	0	0
23. Total underwriting deductions (Lines 18 through 22).....	28,933,589	493,196,328	522,043,525
24. Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	17,533,913	6,445,797
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)	0	8,294,886	5,833,151
26. Net realized capital gains (losses) less capital gains tax of \$(224,349)	0	(2,568,567)	(1,053,769)
27. Net investment gains (losses) (Lines 25 plus 26)	0	5,726,319	4,779,382
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$0) (amount charged off \$0)]	0	0	0
29. Aggregate write-ins for other income or expenses	0	(4,076)	0
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX	23,256,156	11,225,179
31. Federal and foreign income taxes incurred	XXX	4,166,018	1,246,450
32. Net income (loss) (Lines 30 minus 31)	XXX	19,090,138	9,978,729
DETAILS OF WRITE-INS			
0601.	XXX		
0602.	XXX		
0603.	XXX		
0698. Summary of remaining write-ins for Line 6 from overflow page	XXX	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	XXX		
0702.	XXX		
0703.	XXX		
0798. Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.			
1402.			
1403.			
1498. Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901. Regulatory fines	0	(4,076)	0
2902.			
2903.			
2998. Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999. Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	(4,076)	0

STATEMENT OF REVENUE AND EXPENSES (Continued)

	1 Current Year	2 Prior Year
CAPITAL AND SURPLUS ACCOUNT		
33. Capital and surplus prior reporting year.....	139,131,180	131,888,010
34. Net income or (loss) from Line 32	19,090,138	9,978,729
35. Change in valuation basis of aggregate policy and claim reserves	0	0
36. Change in net unrealized capital gains (losses) less capital gains tax of \$ 226,834	853,328	(1,289,941)
37. Change in net unrealized foreign exchange capital gain or (loss)	0	0
38. Change in net deferred income tax	738,926	(364,877)
39. Change in nonadmitted assets	(1,781,077)	1,251,933
40. Change in unauthorized and certified reinsurance	(838,042)	(2,332,674)
41. Change in treasury stock	0	0
42. Change in surplus notes	0	0
43. Cumulative effect of changes in accounting principles.....	0	0
44. Capital Changes:		
44.1 Paid in	0	0
44.2 Transferred from surplus (Stock Dividend).....	0	0
44.3 Transferred to surplus.....	0	0
45. Surplus adjustments:		
45.1 Paid in	0	0
45.2 Transferred to capital (Stock Dividend)	0	0
45.3 Transferred from capital	0	0
46. Dividends to stockholders	(10,000,000)	0
47. Aggregate write-ins for gains or (losses) in surplus	0	0
48. Net change in capital and surplus (Lines 34 to 47)	8,063,273	7,243,170
49. Capital and surplus end of reporting period (Line 33 plus 48)	147,194,453	139,131,180
DETAILS OF WRITE-INS		
4701.		
4702.		
4703.		
4798. Summary of remaining write-ins for Line 47 from overflow page	0	0
4799. Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

CASH FLOW

	1	2
	Current Year	Prior Year
Cash from Operations		
1. Premiums collected net of reinsurance	509,919,264	534,894,485
2. Net investment income	8,398,780	6,362,660
3. Miscellaneous income	0	0
4. Total (Lines 1 through 3)	518,318,044	541,257,145
5. Benefit and loss related payments	426,728,517	459,629,555
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7. Commissions, expenses paid and aggregate write-ins for deductions	74,405,829	56,904,698
8. Dividends paid to policyholders	0	0
9. Federal and foreign income taxes paid (recovered) net of \$0 tax on capital gains (losses)	5,419,076	(1,787,853)
10. Total (Lines 5 through 9)	506,553,422	514,746,400
11. Net cash from operations (Line 4 minus Line 10)	11,764,622	26,510,745
Cash from Investments		
12. Proceeds from investments sold, matured or repaid:		
12.1 Bonds	59,235,028	57,578,689
12.2 Stocks	0	0
12.3 Mortgage loans	0	0
12.4 Real estate	0	0
12.5 Other invested assets	0	0
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	115	88
12.7 Miscellaneous proceeds	1,006,281	0
12.8 Total investment proceeds (Lines 12.1 to 12.7)	60,241,424	57,578,777
13. Cost of investments acquired (long-term only):		
13.1 Bonds	65,772,717	67,883,023
13.2 Stocks	0	0
13.3 Mortgage loans	0	0
13.4 Real estate	0	0
13.5 Other invested assets	0	0
13.6 Miscellaneous applications	0	0
13.7 Total investments acquired (Lines 13.1 to 13.6)	65,772,717	67,883,023
14. Net increase/(decrease) in contract loans and premium notes	0	0
15. Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(5,531,293)	(10,304,246)
Cash from Financing and Miscellaneous Sources		
16. Cash provided (applied):		
16.1 Surplus notes, capital notes	0	0
16.2 Capital and paid in surplus, less treasury stock	0	0
16.3 Borrowed funds	0	0
16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
16.5 Dividends to stockholders	10,000,000	0
16.6 Other cash provided (applied)	(1,321,165)	(7,039,444)
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(11,321,165)	(7,039,444)
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(5,087,836)	9,167,055
19. Cash, cash equivalents and short-term investments:		
19.1 Beginning of year	9,869,090	702,035
19.2 End of year (Line 18 plus Line 19.1)	4,781,254	9,869,090
Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0001. Non-cash investment exchanges	0	2,508,675

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other Health	14 Other Non-Health
		2 Individual	3 Group											
1. Net premium income	511,246,083	0	8,954,135	0	0	0	16,373,917	485,918,031	0	0	0	0	0	0
2. Change in unearned premium reserves and reserve for rate credit	(515,842)	0	(191,524)	0	0	0	(324,318)	0	0	0	0	0	0	0
3. Fee-for-service (net of \$ medical expenses)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
4. Risk revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
5. Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
6. Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7. Total revenues (Lines 1 to 6)	510,730,241	0	8,762,611	0	0	0	16,049,599	485,918,031	0	0	0	0	0	0
8. Hospital/medical benefits	323,318,009	0	4,261,608	0	0	0	7,612,555	311,443,846	0	0	0	0	0	XXX
9. Other professional services	21,024,020	0	534,146	0	0	0	538,071	19,951,803	0	0	0	0	0	XXX
10. Outside referrals	8,305,966	0	129,775	0	0	0	215,242	7,960,949	0	0	0	0	0	XXX
11. Emergency room and out-of-area	16,957,812	0	491,058	0	0	0	468,369	15,998,385	0	0	0	0	0	XXX
12. Prescription drugs	58,311,624	0	1,378,101	0	0	0	4,504,176	52,429,347	0	0	0	0	0	XXX
13. Aggregate write-ins for other hospital and medical incentive pool, withhold adjustments and bonus amounts	10,099,866	0	53,396	0	0	0	164,450	9,882,020	0	0	0	0	0	XXX
15. Subtotal (Lines 8 to 14)	438,017,297	0	6,848,084	0	0	0	13,502,863	417,666,350	0	0	0	0	0	XXX
16. Net reinsurance recoveries	14,987,543	0	0	0	0	0	0	14,987,543	0	0	0	0	0	XXX
17. Total medical and hospital (Lines 15 minus 16)	423,029,754	0	6,848,084	0	0	0	13,502,863	402,678,807	0	0	0	0	0	XXX
18. Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19. Claims adjustment expenses including \$ 9,166,106 cost containment expenses	13,189,207	0	654,224	0	0	0	0	12,534,983	0	0	0	0	0	0
20. General administrative expenses	56,977,367	0	872,191	0	0	0	1,728,784	54,376,392	0	0	0	0	0	0
21. Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
22. Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23. Total underwriting deductions (Lines 17 to 22)	493,196,328	0	8,374,499	0	0	0	15,231,647	469,590,182	0	0	0	0	0	0
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	17,533,913	0	388,112	0	0	0	817,952	16,327,849	0	0	0	0	0	0
DETAILS OF WRITE-INS														
0501.														XXX
0502.														XXX
0503.														XXX
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0601.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
0602.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
0603.		XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
0698. Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.														XXX
1302.														XXX
1303.														XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
1399. Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical) individual	0	0	0	0
2. Comprehensive (hospital and medical) group	8,954,135	0	0	8,954,135
3. Medicare Supplement	0	0	0	0
4. Vision only	0	0	0	0
5. Dental only	0	0	0	0
6. Federal Employees Health Benefits Plan	16,373,917	0	0	16,373,917
7. Title XVIII - Medicare	500,416,103	0	14,498,072	485,918,031
8. Title XIX - Medicaid	0	0	0	0
9. Credit A&H	0	0	0	0
10. Disability Income	0	0	0	0
11. Long-Term Care	0	0	0	0
12. Other health	0	0	0	0
13. Health subtotal (Lines 1 through 12)	525,744,155	0	14,498,072	511,246,083
14. Life	0	0	0	0
15. Property/casualty	0	0	0	0
16. Totals (Lines 13 to 15)	525,744,155	0	14,498,072	511,246,083

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other Health	14 Other Non-Health
		2 Individual	3 Group											
1. Payments during the year:														
1.1 Direct	434,020,037	0	7,167,632	0	0	0	12,577,002	414,275,403	0	0	0	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	16,648,144	0	0	0	0	0	0	16,648,144	0	0	0	0	0	0
1.4 Net	417,371,893	0	7,167,632	0	0	0	12,577,002	397,627,259	0	0	0	0	0	0
2. Paid medical incentive pools and bonuses	9,356,624	0	126,706	0	0	0	165,026	9,064,892	0	0	0	0	0	0
3. Claim liability December 31, current year from Part 2A:														
3.1 Direct	46,414,551	0	924,243	0	0	0	2,794,796	42,695,512	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	1,317,166	0	0	0	0	0	0	1,317,166	0	0	0	0	0	0
3.4 Net	45,097,385	0	924,243	0	0	0	2,794,796	41,378,346	0	0	0	0	0	0
4. Claim reserve December 31, current year from Part 2D:														
4.1 Direct	24,975	0	6,720	0	0	0	18,255	0	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.4 Net	24,975	0	6,720	0	0	0	18,255	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current year	7,756,391	0	68,496	0	0	0	139,223	7,548,672	0	0	0	0	0	0
6. Net health care receivables (a)	(226,906)	0	69,156	0	0	0	47,947	(344,009)	0	0	0	0	0	0
7. Amounts recoverable from reinsurers December 31, current year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8. Claim liability December 31, prior year from Part 2A:														
8.1 Direct	52,750,811	0	1,228,629	0	0	0	1,991,589	49,530,593	0	0	0	0	0	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	2,977,767	0	0	0	0	0	0	2,977,767	0	0	0	0	0	0
8.4 Net	49,773,044	0	1,228,629	0	0	0	1,991,589	46,552,826	0	0	0	0	0	0
9. Claim reserve December 31, prior year from Part 2D:														
9.1 Direct	18,227	0	6,123	0	0	0	12,104	0	0	0	0	0	0	0
9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
9.4 Net	18,227	0	6,123	0	0	0	12,104	0	0	0	0	0	0	0
10. Accrued medical incentive pools and bonuses, prior year	7,013,149	0	141,806	0	0	0	139,799	6,731,544	0	0	0	0	0	0
11. Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Incurred Benefits:														
12.1 Direct	427,917,431	0	6,794,687	0	0	0	13,338,413	407,784,331	0	0	0	0	0	0
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12.3 Reinsurance ceded	14,987,543	0	0	0	0	0	0	14,987,543	0	0	0	0	0	0
12.4 Net	412,929,888	0	6,794,687	0	0	0	13,338,413	392,796,788	0	0	0	0	0	0
13. Incurred medical incentive pools and bonuses	10,099,866	0	53,396	0	0	0	164,450	9,882,020	0	0	0	0	0	0

(a) Excludes \$ 0 loans or advances to providers not yet expensed.

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other Health	14 Other Non-Health
		2 Individual	3 Group											
1. Reported in Process of Adjustment:														
1.1 Direct	6,649,592	0	193,032	0	0	0	607,610	5,848,950	0	0	0	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.4 Net	6,649,592	0	193,032	0	0	0	607,610	5,848,950	0	0	0	0	0	0
2. Incurred but Unreported:														
2.1 Direct	39,764,959	0	731,211	0	0	0	2,187,186	36,846,562	0	0	0	0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	1,317,166	0	0	0	0	0	0	1,317,166	0	0	0	0	0	0
2.4 Net	38,447,793	0	731,211	0	0	0	2,187,186	35,529,396	0	0	0	0	0	0
3. Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4. TOTALS:														
4.1 Direct	46,414,551	0	924,243	0	0	0	2,794,796	42,695,512	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	1,317,166	0	0	0	0	0	0	1,317,166	0	0	0	0	0	0
4.4 Net	45,097,385	0	924,243	0	0	0	2,794,796	41,378,346	0	0	0	0	0	0

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

Line of Business	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5 Claims Incurred In Prior Years (Columns 1 + 3)	6 Estimated Claim Reserve and Claim Liability December 31 of Prior Year
	1	2	3	4		
	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year		
1. Comprehensive (hospital and medical) individual	0	0	0	0	0	0
2. Comprehensive (hospital and medical) group	691,043	6,476,589	35,089	895,874	726,132	1,234,752
3. Medicare Supplement	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Dental Only	0	0	0	0	0	0
6. Federal Employees Health Benefits Plan	1,641,271	10,935,731	14,411	2,798,640	1,655,682	2,003,693
7. Title XVIII - Medicare	46,367,592	351,259,667	1,028,930	40,349,416	47,396,522	46,552,826
8. Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	0	0	0	0	0	0
13. Health subtotal (Lines 1 to 12)	48,699,906	368,671,987	1,078,430	44,043,930	49,778,336	49,791,271
14. Health care receivables (a)	0	3,384,007	0	0	0	3,610,913
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	6,621,733	2,734,891	2,119,093	5,637,298	8,740,826	7,013,149
17. Totals (Lines 13 - 14 + 15 + 16)	55,321,639	368,022,871	3,197,523	49,681,228	58,519,162	53,193,507

(a) Excludes \$ 0 loans or advances to providers not yet expensed.

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	9,887	9,887	9,887	9,887	9,887
2. 2019	74,724	78,720	78,720	78,720	78,720
3. 2020	XXX	42,621	46,696	46,696	46,696
4. 2021	XXX	XXX	17,132	18,890	18,890
5. 2022	XXX	XXX	XXX	6,749	7,539
6. 2023	XXX	XXX	XXX	XXX	6,403

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	41,204	41,204	41,204	41,204	41,204
2. 2019	85,103	89,324	89,324	89,324	89,324
3. 2020	XXX	48,639	53,037	53,037	53,037
4. 2021	XXX	XXX	19,015	20,913	20,913
5. 2022	XXX	XXX	XXX	7,986	7,578
6. 2023	XXX	XXX	XXX	XXX	7,364

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	95,799	78,720	1,847	2.3	80,567	84.1	0	0	80,567	84.1
2. 2020	64,484	46,696	420	0.9	47,116	73.1	0	0	47,116	73.1
3. 2021	21,507	18,890	233	1.2	19,123	88.9	0	0	19,123	88.9
4. 2022	8,281	7,539	118	1.6	7,657	92.5	39	0	7,696	92.9
5. 2023	8,763	6,403	657	10.3	7,060	80.6	961	43	8,064	92.0

12.HM

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019					
3. 2020	XXX				
4. 2021	XXX	XXX			
5. 2022	XXX	XXX	XXX		
6. 2023	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Medicare Supplement

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019					
3. 2020	XXX				
4. 2021	XXX	XXX			
5. 2022	XXX	XXX	XXX		
6. 2023	XXX	XXX	XXX	XXX	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense (Col. 3/2)	4 Percent	5 Claim and Claim Adjustment Expense Payments (Col. 5/1)	6 Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	NONE									
2. 2020										
3. 2021										
4. 2022										
5. 2023										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Dental Only

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019	XXX				
3. 2020	XXX	XXX			
4. 2021	XXX	XXX	XXX		
5. 2022	XXX	XXX	XXX	XXX	
6. 2023	XXX	XXX	XXX	XXX	XXX

Section B - Incurred Health Claims - Dental Only

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019	XXX				
3. 2020	XXX	XXX			
4. 2021	XXX	XXX	XXX		
5. 2022	XXX	XXX	XXX	XXX	
6. 2023	XXX	XXX	XXX	XXX	XXX

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense (Col. 3/2) Percent	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 5/1) Percent	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	NONE									
2. 2020										
3. 2021										
4. 2022										
5. 2023										

12.D0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS
(\$000 Omitted)

Section A - Paid Health Claims - Vision Only

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019					
3. 2020	XXX				
4. 2021	XXX	XXX			
5. 2022	XXX	XXX	XXX		
6. 2023	XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Vision Only

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019					
3. 2020	XXX				
4. 2021	XXX	XXX			
5. 2022	XXX	XXX	XXX		
6. 2023	XXX	XXX	XXX	XXX	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense (Col. 3/2) Percent	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 5/1) Percent	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	NONE									
2. 2020										
3. 2021										
4. 2022										
5. 2023										

12.VO

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

Year in Which Losses Were Incurred		Cumulative Net Amounts Paid				
		1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	2,782	2,782	2,782	2,782	2,782
2.	2019	20,757	22,833	22,833	22,833	22,833
3.	2020	XXX	15,560	17,630	17,630	17,630
4.	2021	XXX	XXX	12,038	14,265	14,265
5.	2022	XXX	XXX	XXX	12,364	14,162
6.	2023	XXX	XXX	XXX	XXX	10,802

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

Year in Which Losses Were Incurred		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
		1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	11,114	11,114	11,114	11,114	11,114
2.	2019	23,607	25,736	25,736	25,736	25,736
3.	2020	XXX	17,965	20,129	20,129	20,129
4.	2021	XXX	XXX	14,033	16,341	16,341
5.	2022	XXX	XXX	XXX	14,427	14,200
6.	2023	XXX	XXX	XXX	XXX	13,716

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	27,293	22,833	0	0.0	22,833	83.7	0	0	22,833	83.7
2. 2020	22,060	17,630	137	0.8	17,767	80.5	0	0	17,767	80.5
3. 2021	20,389	14,265	233	1.6	14,498	71.1	0	0	14,498	71.1
4. 2022	18,115	14,162	237	1.7	14,399	79.5	38	0	14,437	79.7
5. 2023	16,050	10,802	0	0.0	10,802	67.3	2,914	0	13,716	85.5

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	42,990	42,990	42,990	42,990	42,990
2. 2019	528,068	576,742	576,742	576,742	576,742
3. 2020	XXX	452,685	503,343	503,343	503,343
4. 2021	XXX	XXX	436,221	486,540	486,540
5. 2022	XXX	XXX	XXX	382,601	435,335
6. 2023	XXX	XXX	XXX	XXX	350,818

Section B - Incurred Health Claims - Title XVIII

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	132,943	132,943	132,943	132,943	132,943
2. 2019	586,805	637,865	637,865	637,865	637,865
3. 2020	XXX	506,928	562,536	562,536	562,536
4. 2021	XXX	XXX	487,050	540,734	540,734
5. 2022	XXX	XXX	XXX	432,521	438,455
6. 2023	XXX	XXX	XXX	XXX	396,625

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	616,161	576,742	15,408	2.7	592,150	96.1	0	0	592,150	96.1
2. 2020	603,115	503,343	13,028	2.6	516,371	85.6	0	0	516,371	85.6
3. 2021	547,631	486,540	10,287	2.1	496,827	90.7	0	0	496,827	90.7
4. 2022	502,094	435,335	9,875	2.3	445,210	88.7	3,120	0	448,330	89.3
5. 2023	485,918	350,818	12,739	3.6	363,557	74.8	45,807	730	410,094	84.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Title XIX

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019					
3. 2020					
4. 2021					
5. 2022					
6. 2023					

Section B - Incurred Health Claims - Title XIX

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	NONE				
2. 2019					
3. 2020					
4. 2021					
5. 2022					
6. 2023					

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense (Col. 3/2)	4 Percent (Col. 3/2)	5 Claim and Claim Adjustment Expense Payments (Col. 4/2)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	NONE									
2. 2020										
3. 2021										
4. 2022										
5. 2023										

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Other

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid									
	1 2019	2 2020	3 2021	4 2022	5 2023					
1. Prior	NONE									
2. 2019										
3. 2020						XXX				
4. 2021						XXX	XXX			
5. 2022						XXX	XXX	XXX		
6. 2023						XXX	XXX	XXX	XXX	

Section B - Incurred Health Claims - Other

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year									
	1 2019	2 2020	3 2021	4 2022	5 2023					
1. Prior	NONE									
2. 2019										
3. 2020						XXX				
4. 2021						XXX	XXX			
5. 2022						XXX	XXX	XXX		
6. 2023						XXX	XXX	XXX	XXX	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense (Col. 3/2)	4 Percent	5 Claim and Claim Adjustment Expense Payments (Col. 5/1)	6 Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	NONE									
2. 2020										
3. 2021										
4. 2022										
5. 2023										

12.0T

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Grand Total

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	55,659	55,659	55,659	55,659	55,659
2. 2019	623,549	678,295	678,295	678,295	678,295
3. 2020	XXX	510,866	567,669	567,669	567,669
4. 2021	XXX	XXX	465,391	519,695	519,695
5. 2022	XXX	XXX	XXX	401,714	457,036
6. 2023	XXX	XXX	XXX	XXX	368,023

Section B - Incurred Health Claims - Grand Total

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	185,261	185,261	185,261	185,261	185,261
2. 2019	695,515	752,925	752,925	752,925	752,925
3. 2020	XXX	573,532	635,702	635,702	635,702
4. 2021	XXX	XXX	520,098	577,988	577,988
5. 2022	XXX	XXX	XXX	454,934	460,233
6. 2023	XXX	XXX	XXX	XXX	417,705

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payment	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2 + 3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2019	739,253	678,295	17,255	2.5	695,550	94.1	0	0	695,550	94.1
2. 2020	689,659	567,669	13,585	2.4	581,254	84.3	0	0	581,254	84.3
3. 2021	589,527	519,695	10,753	2.1	530,448	90.0	0	0	530,448	90.0
4. 2022	528,490	457,036	10,230	2.2	467,266	88.4	3,197	0	470,463	89.0
5. 2023	510,731	368,023	13,396	3.6	381,419	74.7	49,682	773	431,874	84.6

12.GT

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1 Total	Comprehensive (Hospital & Medical)		4 Medicare Supplement	5 Vision Only	6 Dental Only	7 Federal Employees Health Benefits Plan	8 Title XVIII Medicare	9 Title XIX Medicaid	10 Credit A&H	11 Disability Income	12 Long-Term Care	13 Other
		2 Individual	3 Group										
1. Unearned premium reserves	823	0	823	0	0	0	0	0	0	0	0	0	0
2. Additional policy reserves (a)	0	0	0	0	0	0	0	0	0	0	0	0	0
3. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0	0
4. Reserve for rate credits or experience rating refunds (including \$0 for investment income) ..	32,783,518	0	472,446	0	0	0	1,917,099	30,393,973	0	0	0	0	0
5. Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
6. Totals (gross)	32,784,341	0	473,269	0	0	0	1,917,099	30,393,973	0	0	0	0	0
7. Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
8. Totals (Net)(Page 3, Line 4)	32,784,341	0	473,269	0	0	0	1,917,099	30,393,973	0	0	0	0	0
9. Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0	0	0	0	0
10. Reserve for future contingent benefits	24,975	0	6,720	0	0	0	18,255	0	0	0	0	0	0
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Totals (gross)	24,975	0	6,720	0	0	0	18,255	0	0	0	0	0	0
13. Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
14. Totals (Net)(Page 3, Line 7)	24,975	0	6,720	0	0	0	18,255	0	0	0	0	0	0
DETAILS OF WRITE-INS													
0501.													
0502.													
0503.													
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0
1101.													
1102.													
1103.													
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

	Claim Adjustment Expenses		3 General Administrative Expenses	4 Investment Expenses	5 Total
	1 Cost Containment Expenses	2 Other Claim Adjustment Expenses			
1. Rent (\$0 for occupancy of own building)	16,974	19,337	107,635	2,794	146,740
2. Salary, wages and other benefits	5,686,366	1,888,816	16,314,125	145,042	24,034,349
3. Commissions (less \$0 ceded plus \$0 assumed)	0	0	6,273,998	0	6,273,998
4. Legal fees and expenses	58	148	306,050	319	306,575
5. Certifications and accreditation fees	0	0	0	0	0
6. Auditing, actuarial and other consulting services ...	94,955	81,722	12,197,012	34,491	12,408,180
7. Traveling expenses	7,063	2,518	350,901	1,006	361,488
8. Marketing and advertising	2,523	30,953	5,776,128	(489)	5,809,115
9. Postage, express and telephone	107,782	198,840	1,528,855	111	1,835,588
10. Printing and office supplies	100,641	57,798	2,023,413	101	2,181,953
11. Occupancy, depreciation and amortization	98,683	41,918	(140,601)	615	615
12. Equipment	12,779	52,717	341,405	6	406,907
13. Cost or depreciation of EDP equipment and software	159,556	108,942	1,688,547	5,284	1,962,329
14. Outsourced services including EDP, claims, and other services	2,430,822	1,216,172	7,105,068	27,480	10,779,542
15. Boards, bureaus and association fees	585	365	22,163	237	23,350
16. Insurance, except on real estate	1,443	568	571,415	8	573,434
17. Collection and bank service charges	0	232	295,215	8,637	304,084
18. Group service and administration fees	0	0	0	0	0
19. Reimbursements by uninsured plans	0	0	0	0	0
20. Reimbursements from fiscal intermediaries	0	12	(12)	0	0
21. Real estate expenses	2	0	311,794	3	311,799
22. Real estate taxes	0	0	60,640	0	60,640
23. Taxes, licenses and fees:					
23.1 State and local insurance taxes	0	0	586,190	0	586,190
23.2 State premium taxes	0	0	0	0	0
23.3 Regulatory authority licenses and fees	0	0	(47,977)	0	(47,977)
23.4 Payroll taxes	428,006	142,169	825,681	0	1,395,856
23.5 Other (excluding federal income and real estate taxes)	0	0	19,960	0	19,960
24. Investment expenses not included elsewhere	0	0	0	0	0
25. Aggregate write-ins for expenses	17,868	179,874	459,762	0	657,504
26. Total expenses incurred (Lines 1 to 25)	9,166,106	4,023,101	56,977,367	225,645	(a) 70,392,219
27. Less expenses unpaid December 31, current year	537,056	235,720	639,111	0	1,411,887
28. Add expenses unpaid December 31, prior year	712,846	266,470	1,378,369	0	2,357,685
29. Amounts receivable relating to uninsured plans, prior year	0	0	1,541,726	0	1,541,726
30. Amounts receivable relating to uninsured plans, current year	0	0	2,988,150	0	2,988,150
31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	9,341,896	4,053,851	59,163,049	225,645	72,784,441
DETAILS OF WRITE-INS					
2501. Miscellaneous	17,572	38,991	420,926	0	477,489
2502. Management fee allocation	296	0	(296)	0	0
2503. Loss adjustment expense	0	0	(206,540)	0	(206,540)
2598. Summary of remaining write-ins for Line 25 from overflow page	0	140,883	245,672	0	386,555
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	17,868	179,874	459,762	0	657,504

(a) Includes management fees of \$ 68,934,473 to affiliates and \$ 0 to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

	1 Collected During Year	2 Earned During Year
1. U.S. government bonds	(a) 1,026,114	1,112,583
1.1 Bonds exempt from U.S. tax	(a) 0	0
1.2 Other bonds (unaffiliated)	(a) 6,025,616	5,995,238
1.3 Bonds of affiliates	(a) 0	0
2.1 Preferred stocks (unaffiliated)	(b) 0	0
2.11 Preferred stocks of affiliates	(b) 0	0
2.2 Common stocks (unaffiliated)	0	0
2.21 Common stocks of affiliates	0	0
3. Mortgage loans	(c) 0	0
4. Real estate	(d) 0	0
5. Contract Loans	0	0
6. Cash, cash equivalents and short-term investments	(e) 1,384,248	1,384,248
7. Derivative instruments	(f) 0	0
8. Other invested assets	0	0
9. Aggregate write-ins for investment income	28,462	28,462
10. Total gross investment income	8,464,440	8,520,531
11. Investment expenses		(g) 225,645
12. Investment taxes, licenses and fees, excluding federal income taxes		(g) 0
13. Interest expense		(h) 0
14. Depreciation on real estate and other invested assets		(i) 0
15. Aggregate write-ins for deductions from investment income		0
16. Total deductions (Lines 11 through 15)		225,645
17. Net investment income (Line 10 minus Line 16)		8,294,886
DETAILS OF WRITE-INS		
0901. Miscellaneous interest income	28,462	28,462
0902.		
0903.		
0998. Summary of remaining write-ins for Line 9 from overflow page	0	0
0999. Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	28,462	28,462
1501.		
1502.		
1503.		
1598. Summary of remaining write-ins for Line 15 from overflow page		0
1599. Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

- (a) Includes \$ 681,280 accrual of discount less \$ 841,226 amortization of premium and less \$ 406,096 paid for accrued interest on purchases.
- (b) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued dividends on purchases.
- (c) Includes \$ 0 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued interest on purchases.
- (d) Includes \$ 0 for company's occupancy of its own buildings; and excludes \$ 0 interest on encumbrances.
- (e) Includes \$ 1,383,735 accrual of discount less \$ 0 amortization of premium and less \$ 0 paid for accrued interest on purchases.
- (f) Includes \$ 0 accrual of discount less \$ 0 amortization of premium.
- (g) Includes \$ 0 investment expenses and \$ 0 investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.
- (h) Includes \$ 0 interest on surplus notes and \$ 0 interest on capital notes.
- (i) Includes \$ 0 depreciation on real estate and \$ 0 depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

	1	2	3	4	5
	Realized Gain (Loss) On Sales or Maturity	Other Realized Adjustments	Total Realized Capital Gain (Loss) (Columns 1 + 2)	Change in Unrealized Capital Gain (Loss)	Change in Unrealized Foreign Exchange Capital Gain (Loss)
1. U.S. Government bonds	0	0	0	0	0
1.1 Bonds exempt from U.S. tax	0	0	0	0	0
1.2 Other bonds (unaffiliated)	(1,715,540)	(1,077,492)	(2,793,032)	1,080,162	0
1.3 Bonds of affiliates	0	0	0	0	0
2.1 Preferred stocks (unaffiliated)	0	0	0	0	0
2.11 Preferred stocks of affiliates	0	0	0	0	0
2.2 Common stocks (unaffiliated)	0	0	0	0	0
2.21 Common stocks of affiliates	0	0	0	0	0
3. Mortgage loans	0	0	0	0	0
4. Real estate	0	0	0	0	0
5. Contract loans	0	0	0	0	0
6. Cash, cash equivalents and short-term investments	115	0	115	0	0
7. Derivative instruments	0	0	0	0	0
8. Other invested assets	0	0	0	0	0
9. Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10. Total capital gains (losses)	(1,715,425)	(1,077,492)	(2,792,917)	1,080,162	0
DETAILS OF WRITE-INS					
0901.					
0902.					
0903.					
0998. Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999. Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

EXHIBIT OF NON-ADMITTED ASSETS

	1	2	3
	Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1. Bonds (Schedule D)	0	0	0
2. Stocks (Schedule D):			
2.1 Preferred stocks	0	0	0
2.2 Common stocks	0	0	0
3. Mortgage loans on real estate (Schedule B):			
3.1 First liens	0	0	0
3.2 Other than first liens.....	0	0	0
4. Real estate (Schedule A):			
4.1 Properties occupied by the company	0	0	0
4.2 Properties held for the production of income.....	0	0	0
4.3 Properties held for sale	0	0	0
5. Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)	0	0	0
6. Contract loans	0	0	0
7. Derivatives (Schedule DB)	0	0	0
8. Other invested assets (Schedule BA)	0	0	0
9. Receivables for securities	0	0	0
10. Securities lending reinvested collateral assets (Schedule DL)	0	0	0
11. Aggregate write-ins for invested assets	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13. Title plants (for Title insurers only)	0	0	0
14. Investment income due and accrued	0	0	0
15. Premiums and considerations:			
15.1 Uncollected premiums and agents' balances in the course of collection	603,488	1,032,924	429,436
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due ..	0	0	0
15.3 Accrued retrospective premiums and contracts subject to redetermination	0	0	0
16. Reinsurance:			
16.1 Amounts recoverable from reinsurers	0	0	0
16.2 Funds held by or deposited with reinsured companies	2,279,876	0	(2,279,876)
16.3 Other amounts receivable under reinsurance contracts	0	0	0
17. Amounts receivable relating to uninsured plans	0	0	0
18.1 Current federal and foreign income tax recoverable and interest thereon	0	0	0
18.2 Net deferred tax asset	0	0	0
19. Guaranty funds receivable or on deposit	0	0	0
20. Electronic data processing equipment and software	0	0	0
21. Furniture and equipment, including health care delivery assets	0	0	0
22. Net adjustment in assets and liabilities due to foreign exchange rates	0	0	0
23. Receivable from parent, subsidiaries and affiliates	0	0	0
24. Health care and other amounts receivable	584,463	653,826	69,363
25. Aggregate write-ins for other than invested assets	0	0	0
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	3,467,827	1,686,750	(1,781,077)
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
28. Total (Lines 26 and 27)	3,467,827	1,686,750	(1,781,077)
DETAILS OF WRITE-INS			
1101.			
1102.			
1103.			
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.			
2502.			
2503.			
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	0	0	0

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

Source of Enrollment	Total Members at End of					6 Current Year Member Months
	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	
1. Health Maintenance Organizations	38,039	33,746	32,941	32,344	31,910	395,429
2. Provider Service Organizations	0	0	0	0	0	0
3. Preferred Provider Organizations	0	0	0	0	0	0
4. Point of Service	467	464	471	420	434	5,364
5. Indemnity Only	0	0	0	0	0	0
6. Aggregate write-ins for other lines of business.....	0	0	0	0	0	0
7. Total	38,506	34,210	33,412	32,764	32,344	400,793
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

NOTES TO FINANCIAL STATEMENTS

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying statutory financial statements of Aetna Health Inc. (a New Jersey corporation) (the “Company”), indirectly a wholly-owned subsidiary of CVS Health Corporation (“CVS Health”), have been prepared in conformity with accounting practices prescribed or permitted by the State of New Jersey Department of Banking and Insurance (“New Jersey Department”) (“New Jersey Accounting Practices”). The New Jersey Department recognizes statutory accounting practices prescribed or permitted by the State of New Jersey for determining and reporting the financial condition and results of operations of an insurance company, which include accounting practices and procedures adopted by the National Association of Insurance Commissioners’ (“NAIC”) *Accounting Practices and Procedures Manual*. (“NAIC SAP”).

A reconciliation of the Company’s net income and capital and surplus between NAIC SAP and practices prescribed and permitted by the State of New Jersey for the years ending December 31, 2023 and 2022 is as follows:

	SSAP #	F/S Page	F/S Line #	2023	2022
NET INCOME					
(1) Aetna Health Inc. (a New Jersey corporation) state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 19,090,138	\$ 9,978,729
(2) State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(3) State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(4) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 19,090,138	\$ 9,978,729
SURPLUS					
(5) Aetna Health Inc. (a New Jersey corporation) state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 147,194,453	\$ 139,131,180
(6) State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(7) State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(8) NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 147,194,453	\$ 139,131,180

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these financial statements in conformity with New Jersey Accounting Practices requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses. Actual results could differ from those estimates.

C. Accounting Policies

The Company applies the following significant accounting policies:

(1) Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments, consisting primarily of money market instruments and other debt issues with an original maturity of up to one year, are carried at amortized cost. Short-term investments consist primarily of investments purchased with an original maturity date of greater than three months but less than one year. Cash equivalents consist of highly liquid instruments, which mature within three months from the date of purchase. The carrying amount of cash, cash equivalents and short-term investments approximates fair value. Cash accounts with positive balances shall not be reported separately from cash accounts with negative balances. If in the aggregate, the reporting entity has a net negative cash balance, it shall be reported as a negative asset and shall not be recorded as a liability.

(2) Bonds

Bonds, which include special deposits, are carried at amortized cost except for those bonds with an NAIC designation of 3 through 6, which are carried at the lower of amortized cost or fair value. The amount carried at fair value is not material to the financial statements. Bond premiums and discounts are amortized using the scientific interest method. When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of bonds. This is used primarily for U.S. government securities. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company estimates fair

NOTES TO FINANCIAL STATEMENTS

values using valuation methodologies based on available and observable market information or by using a matrix pricing model. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. The Company had no investments where fair value was determined using broker quotes or an internal analysis of financial performance and cash flow projections at December 31, 2023 or 2022. Bonds include all investments whose maturity is greater than one year when purchased. All adjustments between amortized cost and carrying value are reflected in unrealized capital gains and losses and are reported as direct adjustments to surplus.

Bonds are recorded as purchases or sales on the trade date.

The Company periodically reviews its bonds to determine whether a decline in fair value below the carrying value is other-than-temporary. For bonds, other than loan-backed and structured securities ("LB&SS") discussed in Note 1 C. (6) below, an other-than-temporary impairment ("OTTI") shall be recorded if it is probable that the Company will be unable to collect all amounts due according to the contractual terms in effect at the date of acquisition. Declines deemed to be OTTI in the cost basis are recognized as realized capital losses. Yield-related impairments are deemed other-than-temporary when the Company intends to sell an investment at the reporting date before recovery of the cost of the investment.

The Company analyzes all relevant facts and circumstances for each investment when performing its analysis to determine whether an OTTI exists. Among the factors considered in evaluating whether a decline is other-than-temporary, management considers whether the decline in fair value results from a change in the quality of the investment security itself, whether the decline results from a downward movement in the market as a whole, the prospects for realizing the carrying value of the bond based on the investee's current and short-term prospects for recovery and other factors. The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from the Company's expectations and the risk that facts and circumstances factored into its assessment may change with the passage of time. Unexpected changes to market factors and circumstances that were not present in past reporting periods may result in a current period decision to sell securities that were not other-than-temporarily-impaired in prior reporting periods.

The Company had no Securities Valuation Office-identified investments that are being reported at a different measurement method from the prior year annual statement.

(3) Common Stocks

The Company did not own any common stock at December 31, 2023 or 2022.

(4) Preferred Stocks

The Company did not own any preferred stock at December 31, 2023 or 2022.

(5) Mortgage Loans

The Company did not have any mortgage loans at December 31, 2023 or 2022.

(6) Loan-Backed and Structured Securities

LB&SS are carried at amortized cost adjusted for unamortized premiums and discounts and are accounted for using the retrospective adjustment method. Premiums and discounts on loan-backed and structured securities are amortized using the scientific method over the estimated remaining term of the securities, adjusted for anticipated prepayments.

For LB&SS, the Company records OTTI when the fair value of the loan-backed or structured security is less than the amortized cost basis at the balance sheet date and (1) the Company intends to sell the investment, or (2) the Company does not have the intent and ability to retain the investment for the time sufficient to recover the amortized cost basis, or (3) the Company does not expect to recover the entire amortized cost basis of the security, even if it does not intend to sell the security and has the intent and ability to hold. If it is determined an OTTI has occurred because of (1) or (2), the amount of the OTTI is equal to the difference between the amortized cost and the fair value of the security at the balance sheet date and this difference is recorded as a realized capital loss. If it is determined an OTTI has occurred because of (3), the amount of the OTTI is equal to the difference between the amortized cost and the present value of cash flows expected to be collected, discounted at the loan-backed or structured security's effective interest rate and this difference is also accounted for as a realized capital loss.

(7) Investments in Subsidiaries, Controlled or Affiliated Companies

The Company did not have any investments in subsidiaries, controlled or affiliated companies at December 31, 2023 or 2022.

(8) Investments in Joint Ventures, Partnerships and Limited Liability Companies

The Company did not have any investments in any joint ventures, partnerships and limited liability companies at December 31, 2023 or 2022.

(9) Derivatives

NOTES TO FINANCIAL STATEMENTS

The Company did not have any derivatives at December 31, 2023 or 2022.

(10) Aggregate Health Policy Reserves and Related Expenses

Premium deficiency reserves (“PDR”) are recognized when it is probable that the expected future hospital and medical costs, including maintenance costs, will exceed anticipated future premiums and reinsurance recoveries on existing contracts. Anticipated investment income is not considered in the calculation of any PDR. For purposes of calculating a PDR, contracts are grouped in a manner consistent with the method of acquiring, servicing and measuring the profitability of such contracts.

Unearned premium reserves (“UEP”) are recognized for premiums that are recorded by the Company that have not been earned as of the statement date. The UEP balances of \$823 and \$869 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2023 and 2022, respectively.

The Company is required to make premium rebate payments to customers that are enrolled under certain health insurance policies if specific minimum annual medical loss ratios (“MLR”) were not met in the prior year. The Company's results for full year 2023 and 2022 include estimates of \$1,361,792 and \$825,904, respectively, of minimum MLR rebates, which were included in aggregate health policy reserves in the Statutory Statements of Liabilities and Capital and Surplus.

The Company contracts with the Office of Personnel Management (“OPM”) to provide managed health care services under the Federal Employees Health Benefits (“FEHB”) program in its service areas. OPM regulations require that FEHB plans meet a FEHB program-specific MLR by plan code and market. The Company reported minimum FEHB program MLR rebate estimates of \$560,000 and \$580,000 in aggregate health policy reserves at December 31, 2023 and 2022, respectively. The Company reported Federal Contingency Reserves of \$467,753 and \$542,907 in aggregate health policy reserves at December 31, 2023 and 2022, respectively.

For Medicare plans, the Company’s annual contract with Centers for Medicare & Medicaid Services (“CMS”) provides a risk-sharing arrangement to limit exposure to unexpected expenses. The risk-sharing arrangement provides a risk corridor whereby the amount the Company received in premiums from members and CMS based on its annual bid is compared to actual drug costs incurred during the contract year. Based on the risk corridor provision and Part D activity-to-date, estimated risk-sharing payables of \$282,170 and \$313,176 were included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus at December 31, 2023 and 2022, respectively.

The Company reported liabilities associated with contracts subject to redetermination as aggregate health policy reserves in accordance with SSAP No. 54 - Revised - *Individual and Group and Accident Health Contracts* (“SSAP No. 54”). Liabilities associated with estimated adjustments to premium payments to the Company's Medicare plans based on the health status of its Medicare members are included as part of the Company's contracts subject to redetermination. Amounts related to these liabilities are \$30,111,803 and \$22,132,362 and are included in aggregate health policy reserves at December 31, 2023 and 2022, respectively.

(11) Hospital and Medical Costs and Claims Adjustment Expenses and Related Reserves

Hospital and medical costs consist principally of fee-for-service medical claims and capitation costs. Claims unpaid and aggregate health claim reserves include the Company's estimate of payments to be made on claims reported but not yet paid and for health care services rendered to enrollees but not yet reported to the Company as of the Statutory Statements of Assets and Liabilities, Capital and Surplus date. Such estimates are developed using actuarial principles and assumptions, which consider, among other things, historical and projected claim submission and processing payment patterns, medical cost trends, historical utilization of health care services, claim inventory levels, medical inflation, contract requirement changes in membership and product mix, seasonality and other relevant factors. The Company reflects changes in estimates in hospital and medical costs in the Statutory Statements of Revenue and Expenses in the period they are determined. Capitation costs, which are recorded in hospital and medical expenses in the Statutory Statements of Revenue and Expenses, represent contractual monthly fees paid to participating physicians and other medical providers for providing medical care, regardless of the medical services provided to the enrollee.

The Company uses the triangulation method to estimate reserves for claims incurred but not reported. The method of triangulation makes estimates of completion factors that are then applied to the total paid claims (net of coordination of benefits) to date for each incurral month. This provides an estimate of the total projected incurred claims and total amount outstanding or claims incurred but not reported (claims unpaid). For the most current dates of service where there is insufficient paid claim data to rely solely on the triangulation method, the Company examines cost and utilization trends as well as environmental factors, plan changes, provider contracts, changes in membership and/or benefits, and historical seasonal patterns to estimate the reserve required for these months.

Claims adjustment expenses, which include cost containment expenses, represent the costs incurred related to the claim settlement process such as costs to record, process and adjust claims. These expenses are included in the Company's management agreement with an affiliate described in Note 10.

(12) Capitalization Policy

The Company has not modified its capitalization policy from the prior period.

(13) Pharmaceutical Rebate Receivables

NOTES TO FINANCIAL STATEMENTS

The Company estimates pharmaceutical rebate receivables based upon historical payment trends, actual utilization and other variables. Pharmaceutical rebates for a quarter are billed to the vendor within one month of the completion of the quarter with any adjustment to previously recorded amounts reflected at the time of billing. The Company reports pharmaceutical rebate receivables as health care receivables. Pharmacy rebate receivables not in accordance with SSAP No. 84 – *Health Care and Government Insured Plan Receivables* or are over 90 days past due are nonadmitted. All rebates are processed and settled monthly with an affiliated entity, including adjustments to previously billed periods. The pharmaceutical rebate receivables are more fully discussed in Note 28.

(14) Premiums and Amounts Due and Unpaid

Prepaid premium revenue for health care products is recognized as income in the month in which enrollees are entitled to health care services. Premiums collected before the effective period are reported as premiums received in advance. Premiums related to unexpired contractual coverage periods are reported as unearned premiums and are included in aggregate health policy reserves in the Statutory Statements of Liabilities, Capital and Surplus.

Nonadmitted amounts consist of all premiums due and unpaid greater than 90 days past due, with the exception of amounts due under government insured plans, which may be admitted assets under certain circumstances. In addition, for any customer for which the premiums due and unpaid greater than 90 days past due is more than a de minimus portion of the entire balance of premiums due and unpaid for that customer, the entire balance of premiums due and unpaid for that customer is nonadmitted. Management also performs a specific review of accounts and based on the results of the review, additional amounts may be nonadmitted. Uncollectible amounts are generally written-off and charged to revenue in the period in which the customer reconciliations are completed and agreed to by the customer (retroactivity) or when the account is determined to be uncollectible by the Company.

Through the Company's Medicare Advantage Part D annual contract with CMS, the Company receives monthly premium payments from CMS and members, as determined by the Company's annual bid process. The Company recognizes the revenue related to the CMS contract ratably over the term of its annual contract.

The CMS payment is subject to risk sharing provisions through the CMS risk corridor provision, which is accounted for as a retrospectively rated contract in accordance with SSAP No. 66 - *Retrospectively Rated Contracts*. Receivables related to the CMS risk corridor provision are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

The Company's CMS payment is also subject to the CMS risk adjustment process for each member, which is accounted for as a contract subject to redetermination in accordance with SSAP No. 54. Receivables related to the CMS risk adjustment process are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

(15) Aggregate Health Claim Reserves

The reserve for future contingent benefits includes the estimated cost of services that will continue to be incurred after the Statutory Statements of Liabilities, Capital and Surplus date if the Company is obligated to pay for such services in accordance with contract provisions or regulatory requirements. These balances are recorded in aggregate health claim reserves in the Statutory Statements of Liabilities, Capital and Surplus and are estimated using a percentage of current hospital and medical costs, which is based on the Company's historical cost experience.

(16) Investment Income Due and Accrued

Accrued investment income consists primarily of interest. Interest is recognized on an accrual basis and dividends are recorded as earned on the ex-dividend date. Due and accrued income is not recorded on: (a) bonds in default; and (b) bonds delinquent more than 90 days or where collection of interest is improbable. At December 31, 2023 and 2022, the Company did not have any nonadmitted investment income due and accrued.

(17) Covered and Uncovered Expenses and Related Liabilities

Covered expenses and related liabilities represent costs for health care expenses for which a member is not responsible in the event of the insolvency of the Company. Uncovered expenses and related liabilities represent costs to the Company for health care services that are the obligation of the Company and for which a member may also be liable in the event of the Company's insolvency.

(18) The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's (collectively, the "ACA") Risk Adjustment

The ACA established a permanent risk adjustment program to transfer funds from qualified individual and small group insurance plans with below average risk scores to plans with above average risk scores. Based on the risk of the Company's qualified plan members relative to the average risk of members of other qualified plans in comparable markets, the Company estimates its ultimate risk adjustment receivable or payable for the current calendar year and reflects the impact as an adjustment to its premium revenue in accordance with SSAP No. 107 - Risk-Sharing Provisions of the Affordable Care Act ("SSAP No. 107"). ACA Risk Adjustment payables are included in aggregate health policy reserves on the Statutory Statements of Liabilities, Capital and Surplus. ACA Risk Adjustment receivables are included in accrued retrospective premiums and contracts subject to redetermination on the Statutory Statements of Assets.

NOTES TO FINANCIAL STATEMENTS

(19) Reinsurance

In the normal course of business, the Company seeks to reduce the loss that may arise from catastrophes or other events that cause unfavorable underwriting results and to help balance its risks and capital by reinsuring certain levels of risk with other insurance enterprises. The reinsurance coverage does not relieve the Company of its primary obligations. Reinsurance premiums and reserves related to reinsured business are accounted for on a basis consistent with those used in accounting for the original policies issued and the terms of the reinsurance contracts. Premiums and claims ceded and the related unpaid reserves have been reported as reductions of these items. The reinsurance agreements are more fully discussed in Note 23.

(20) Federal and State Income Taxes

Aetna Inc. ("Aetna") and its wholly-owned subsidiaries are included in the consolidated federal income tax return of its ultimate parent company, CVS Health, pursuant to the terms of a tax sharing agreement. In accordance with the agreement, the Company's current federal and state income tax provisions are generally computed as if the Company were filing a separate federal and state income tax return; current income tax benefits, including those resulting from net operating losses, are recognized to the extent expected to be realized in the consolidated return. Pursuant to the agreement, the Company has the enforceable right to recoup federal and state income taxes paid in prior years in the event of future net losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal and state income taxes.

Income taxes are accounted for under the asset and liability method. Deferred income tax assets ("DTAs") and liabilities ("DTLs") represent the expected future tax consequences of temporary differences generated by statutory accounting as defined in SSAP No. 101 - *Income Taxes*. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. DTAs and DTLs are computed by means of identifying temporary differences which are measured using a balance sheet approach whereby statutory and tax basis balance sheets are compared. Current income tax recoverables include all current income taxes, including interest, reasonably expected to be recovered in a subsequent accounting period.

Pursuant to SSAP No. 101, gross DTAs are first reduced by a statutory valuation allowance adjustment to an amount that is more likely than not to be realized ("adjusted gross DTAs"). Adjusted gross DTAs are then admitted in an amount equal to the sum of paragraphs a. b. and c. below:

- a. Federal income taxes paid in prior years that can be recovered through loss carrybacks for existing temporary differences that reverse during a timeframe corresponding with Internal Revenue Code ("IRC") tax loss carryback provisions.
- b. The amount of adjusted gross DTAs, after the application of paragraph a. above, expected to be realized within the applicable period and that is no greater than the applicable percentage as determined using the applicable Realization Threshold Limitation Table. The applicable period refers to the number of years in which the DTA will reverse in the Company's tax return and the applicable percentage refers to the percentage of the Company's statutory capital and surplus as required to be shown on the statutory balance sheet adjusted to exclude any net DTAs, electronic data processing equipment and operating system software and any net positive goodwill ("Stat Cap ExDTA").

The Realization Threshold Limitation Tables allow DTAs to be admitted based upon either realization within 3 years and 15% of Stat Cap ExDTA, 1 year and 10% of Stat Cap ExDTA, or no DTA admitted pursuant to this paragraph b. In general, the Realization Threshold Limitation Tables allow the Company to admit more DTAs if total DTAs as reported by the Company are a smaller percentage of statutory capital and surplus.

- c. The amount of gross DTAs, after the application of paragraphs a. and b. above that can be offset against existing gross DTLs. In applying this offset, the Company considers the character (i.e. ordinary versus capital) of the DTAs and DTLs such that offsetting would be permitted in the tax return under existing enacted federal income tax laws and regulations and the reversal patterns of temporary differences.

Changes in DTAs and DTLs are recognized as a separate component of gains and losses in surplus ("Change in net deferred income tax") except to the extent allocated to changes in unrealized gains and losses. Changes in DTAs and DTLs allocated to unrealized gains and losses are netted against the related changes in unrealized gains and losses and are reported as "Change in net unrealized capital gains (losses)", also a separate component of gains and losses in surplus.

The Company is subject to state income taxes in various states. State income tax expense is recorded in general administrative expenses in the Statutory Statements of Revenue and Expenses. For the years ended December 31, 2023 and 2022, the Company incurred state income tax expenses of \$586,190 and \$212,119, respectively.

The Company had no state income tax payables at December 31, 2023. The Company had \$32,604 of state income tax payables at December 31, 2022. These balances were included in general expenses due or accrued in the Statutory Statements of Liabilities, Capital and Surplus.

The Company had \$231,382 of state income tax receivables at December 31, 2023. The Company had no state income tax receivables at December 31, 2022. These balances were included as aggregate write-ins for other than invested assets in the Statutory Statements of Assets.

NOTES TO FINANCIAL STATEMENTS

D. Going Concern

As of February 29, 2024, management evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern and management has determined that it is not probable that the Company will be unable to meet its obligations as they become due within one year after the financial statements are available to be issued. Management will continuously evaluate the Company's ability to continue as a going concern and will take appropriate action and will make appropriate disclosures if there is any change in any condition or events that would raise substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

The Company did not have any accounting changes or correction of errors in the years ended December 31, 2023 and 2022.

3. Business Combinations and Goodwill

The Company was not a part of any business combinations that involved the statutory purchase method, a statutory merger, an assumption reinsurance, or an impairment loss in the years ending December 31, 2023 and 2022.

4. Discontinued Operations

The Company did not have any operations receiving discontinued operations accounting treatment during the years ending December 31, 2023 and 2022.

5. Investments

A. The Company did not have any mortgage loans, including Mezzanine Real Estate Loans, at December 31, 2023 or 2022.

B. The Company did not have any debt restructuring in the years ending December 31, 2023 or 2022.

C. The Company did not have any reverse mortgages at December 31, 2023 or 2022.

D. Loan-Backed Securities

(1) Prepayment assumptions for single class and multi-class mortgage-backed/loan-backed securities were obtained from industry market sources.

(2) The Company did not recognize any OTTI on loan-backed and structured securities in which the Company had the (1) intent to sell, (2) did not have the intent and ability to retain for a period of time sufficient to recover the amortized cost basis or (3) present value of cash flows expected to be collected is less than the amortized cost basis of the securities in accordance with SSAP No. 43R - *Loan-Backed and Structured Securities* ("SSAP No. 43R") at December 31, 2023.

(3) The Company had no recognized OTTI on loan-backed and structured securities currently held, in which the present value of cash flows expected to be collected is less than the amortized cost basis at December 31, 2023.

(4) The Company's unrealized loss position on loan-backed and structured securities held by the Company at December 31, 2023 is as follows:

a. The aggregate amount of unrealized losses:

1. Less than 12 Months	\$	(2,231)
2. 12 Months or Longer		(632,428)

b. The aggregate related fair value of securities with unrealized losses:

1. Less than 12 Months	\$	4,058,257
2. 12 Months or Longer		8,934,092

(5) The Company has reviewed the loan-backed and structured securities in accordance with SSAP No. 43R in the table above and has concluded that these are performing assets generating investment income to support the needs of the business. Furthermore, the Company has no intention to sell the securities at December 31, 2023 before their cost can be recovered and does have the intent and ability to retain the securities for the time sufficient to recover the amortized cost basis; therefore, no OTTI write-down to fair value was determined to have occurred on these securities.

E. The Company had no dollar repurchase agreements and/or securities lending transactions at December 31, 2023.

F. The Company did not have any repurchase agreements transactions accounted for as secured borrowing at December 31, 2023.

G. The Company did not have any reverse repurchase agreements transactions accounted for as secured borrowing at December 31, 2023.

H. The Company did not have any repurchase agreements transactions accounted for as a sale at December 31, 2023.

I. The Company did not have any reverse repurchase agreements transactions accounted for as a sale at December 31, 2023.

NOTES TO FINANCIAL STATEMENTS

- J. The Company did not have any real estate at December 31, 2023.
- K. The Company did not have any low-income housing tax credits at December 31, 2023 or 2022.
- L. Restricted Assets

(1) Restricted assets (including pledged):

Restricted Asset Category	1 Total Gross (Admitted & Nonadmitted) Restricted from Current Year	2 Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	3 Increase/ (Decrease) (1 minus 2)	4 Total Current Year Nonadmitted Restricted	5 Total Current Year Admitted Restricted (1 minus 4)	6 Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	7 Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown						—	—
b. Collateral held under security lending agreements						—	—
c. Subject to repurchase agreements						—	—
d. Subject to reverse repurchase agreements						—	—
e. Subject to dollar repurchase agreements						—	—
f. Subject to dollar reverse repurchase agreements						—	—
g. Placed under option contracts						—	—
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock						—	—
i. FHLB capital stock						—	—
j. On deposit with states	\$ 81,770,802	\$ 91,205,950	\$ (9,435,148)	—	\$ 81,770,802	32.159	32.603
k. On deposit with other regulatory bodies						—	—
l. Pledged collateral to FHLB (including assets backing funding agreements)						—	—
m. Pledged as collateral not captured in other categories						—	—
n. Other restricted assets						—	—
o. Total Restricted Assets (Sum of a through n)	\$ 81,770,802	\$ 91,205,950	\$ (9,435,148)	\$ —	\$ 81,770,802	32.159	32.603

(a) Column 1 divided by Asset Page, Column 1, Line 28
(b) Column 5 divided by Asset Page, Column 3, Line 28

- (2) The Company did not have any assets pledged as collateral not captured in other categories at December 31, 2023 or 2022.
- (3) The Company did not have any other restricted assets at December 31, 2023 or 2022.
- (4) The Company did not have any collateral received and reflected within its financial statements at December 31, 2023.

- M. The Company did not have any working capital finance investments at December 31, 2023.
- N. The Company did not have any offsetting and netting of derivative, repurchase and reverse repurchase, and securities borrowing and securities lending assets or liabilities at December 31, 2023.
- O. The Company did not have any 5GI securities at December 31, 2023 or 2022.
- P. The Company did not have any short sales at December 31, 2023.
- Q. Prepayment Penalty and Acceleration Fees at December 31, 2023:

Prepayment Penalty and Acceleration Fees

	<u>General Account</u>
1. Number of CUSIPs	9
2. Aggregate Amount of Investment Income	\$ 47,766

R. The Company did not participate in any qualified cash pools at December 31, 2023.

6. Joint Ventures, Partnerships, and Limited Liability Companies

- A. The Company did not have any joint ventures, partnerships, or limited liability companies that exceeded 10% of its admitted assets at December 31, 2023 or 2022.

NOTES TO FINANCIAL STATEMENTS

B. The Company does not have any impaired investments in joint ventures, partnerships, or limited liability companies at December 31, 2023 or 2022.

7. Investment Income

A. Due and accrued income was excluded from surplus on the following bases:

Bonds - where collection of interest is uncertain.

B. There was no amount excluded at December 31, 2023 or 2022.

C. The gross, nonadmitted and admitted amounts for interest income due and accrued at

Interest Income Due and Accrued	Amount
1. Gross	\$ 1,978,531
2. Nonadmitted	—
3. Admitted	1,978,531

D. There were no amounts for aggregate deferred interest at December 31, 2023.

E. There were no cumulative amounts for paid-in-kind interest included in the current principal balance at December 31, 2023.

8. Derivative Instruments

The Company did not have any derivative instruments at December 31, 2023 or 2022.

9. Income Taxes

A.

(1) The components of the net DTAs recognized in the Company's Statutory Statements of Assets and Liabilities, Capital and Surplus are as follows:

	12/31/2023			12/31/2022			Change		
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
(a) Gross Deferred Tax Assets	\$ 1,124,847	\$ 804,542	\$ 1,929,389	\$ 658,997	\$ 767,454	\$ 1,426,451	\$ 465,850	\$ 37,088	\$ 502,938
(b) Statutory Valuation Allowance Adjustment	—	203,652	203,652	—	186,957	186,957	—	16,695	16,695
(c) Adjusted Gross Deferred Tax Assets (1a - 1b)	1,124,847	600,890	1,725,737	658,997	580,497	1,239,494	465,850	20,393	486,243
(d) Deferred Tax Assets Nonadmitted	—	—	—	—	—	—	—	—	—
(e) Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	1,124,847	600,890	1,725,737	658,997	580,497	1,239,494	465,850	20,393	486,243
(f) Deferred Tax Liabilities	262,427	529,902	792,329	264,994	553,184	818,178	(2,567)	(23,282)	(25,849)
(g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 862,420	\$ 70,988	\$ 933,408	\$ 394,003	\$ 27,313	\$ 421,316	\$ 468,417	\$ 43,675	\$ 512,092

(2) The amount of admitted gross DTAs admitted under each component of SSAP No. 101:

NOTES TO FINANCIAL STATEMENTS

	12/31/2023			12/31/2022			Change		
	(1) Ordinary	(2) Capital	(3) (Col. 1 + 2) Total	(4) Ordinary	(5) Capital	(6) (Col. 4 + 5) Total	(7) (Col. 1 - 4) Ordinary	(8) (Col. 2 - 5) Capital	(9) (Col. 7 + 8) Total
Admission Calculation Components SSAP No. 101									
(a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks.	\$ 1,069,053	\$ 70,990	\$ 1,140,043	\$ 626,591	\$ 27,312	\$ 653,903	\$ 442,462	\$ 43,678	\$ 486,140
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	44,921	—	44,921	21,387	—	21,387	23,534	—	23,534
1. Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date.	44,921	—	44,921	21,387	—	21,387	23,534	—	23,534
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XX	XX	21,939,157	XX	XX	20,806,480	XX	XX	1,132,677
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	10,873	529,900	540,773	11,019	553,185	564,204	(146)	(23,285)	(23,431)
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total 2(a) + 2(b) + 2(c)	\$ 1,124,847	\$ 600,890	\$ 1,725,737	\$ 658,997	\$ 580,497	\$ 1,239,494	\$ 465,850	\$ 20,393	\$ 486,243

(3)

	2023	2022
(a) Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.	880 %	716 %
(b) Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.	\$ 146,261,045	\$ 138,709,864

(4) The impact of tax planning strategies is as follows:

	12/31/2023		12/31/2022		Change	
	(1) Ordinary	(2) Capital	(3) Ordinary	(4) Capital	(5) (Col. 1 - 3) Ordinary	(6) (Col. 2 - 4) Capital
Impact of Tax Planning Strategies:						
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.						
1. Adjusted Gross DTAs amount from Note 9A1(c)	\$ 1,124,847	\$ 600,890	\$ 658,997	\$ 580,497	\$ 465,850	\$ 20,393
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	— %	— %	— %	— %	— %	— %
3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	1,124,847	600,890	658,997	580,497	465,850	20,393
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	— %	— %	— %	— %	— %	— %

(b) Do the Company's tax-planning strategies include the use of reinsurance? Yes [] No [X]

B. There are no DTLs that were not recognized at December 31, 2023 or 2022.

C. Current income taxes incurred consist of the following major components:

NOTES TO FINANCIAL STATEMENTS

	(1) 12/31/2023	(2) 12/31/2022	(3) (Col. 1 - 2) Change
1. Current Income Tax			
(a) Federal	\$ 4,166,018	\$ 1,246,450	\$ 2,919,568
(b) Foreign	—	—	—
(c) Subtotal (1a+1b)	4,166,018	1,246,450	2,919,568
(d) Federal income tax on net capital gains	(224,349)	(41,621)	(182,728)
(e) Utilization of capital loss carry-forwards	—	—	—
(f) Other	—	—	—
(g) Federal and foreign income taxes incurred (1c+1d+1e+1f)	3,941,669	1,204,829	2,736,840
2. Deferred Tax Assets:			
(a) Ordinary:			
(1) Discounting of unpaid losses	160,048	158,807	1,241
(2) Unearned premium reserve	69,719	28,099	41,620
(3) Policyholder reserves	—	—	—
(4) Investments	—	—	—
(5) Deferred acquisition costs	—	—	—
(6) Policyholder dividends accrual	—	—	—
(7) Fixed assets	—	—	—
(8) Compensation and benefits accrual	—	—	—
(9) Pension accrual	—	—	—
(10) Receivables - nonadmitted	728,243	354,217	374,026
(11) Net operating loss carry-forward	—	—	—
(12) Tax credit carry-forward	—	—	—
(13) Other	166,837	117,874	48,963
(99) Subtotal (sum of 2a1 through 2a13)	1,124,847	658,997	465,850
(b) Statutory valuation allowance adjustment	—	—	—
(c) Nonadmitted	—	—	—
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	1,124,847	658,997	465,850
(e) Capital:			
(1) Investments	804,542	767,454	37,088
(2) Net capital loss carry-forward	—	—	—
(3) Real estate	—	—	—
(4) Other	—	—	—
(99) Subtotal (2e1+2e2+2e3+2e4)	804,542	767,454	37,088
(f) Statutory valuation allowance adjustment	203,652	186,957	16,695
(g) Nonadmitted	—	—	—
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	600,890	580,497	20,393
(i) Admitted deferred tax assets (2d + 2h)	1,725,737	1,239,494	486,243
3. Deferred Tax Liabilities:			
(a) Ordinary:			
(1) Investments	67,109	20,225	46,884
(2) Fixed assets	—	—	—
(3) Deferred and uncollected premium	—	—	—
(4) Policyholder reserves	—	—	—
(5) Other	195,318	244,769	(49,451)
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	262,427	264,994	(2,567)
(b) Capital:			
(1) Investments	529,902	553,184	(23,282)
(2) Real estate	—	—	—
(3) Other	—	—	—
(99) Subtotal (3b1+3b2+3b3)	529,902	553,184	(23,282)
(c) Deferred tax liabilities (3a99 + 3b99)	792,329	818,178	(25,849)
4. Net deferred tax assets/liabilities (2i - 3c)	\$ 933,408	\$ 421,316	\$ 512,092

The change in net deferred income taxes is comprised of the following:

	12/31/2023	12/31/2022	Change
Total Deferred Tax Assets	\$ 1,725,737	\$ 1,239,494	\$ 486,243
Total Deferred Tax Liabilities	(792,329)	(818,178)	25,849
Net Deferred Tax Assets/(Liabilities)	933,408	421,316	512,092
Tax Effect of Unrealized Gains/(Losses)			226,834
Change in Net Deferred Income Tax			\$ 738,926

NOTES TO FINANCIAL STATEMENTS

The valuation allowance adjustment to gross DTAs was \$203,652 for December 31, 2023. The valuation allowance adjustment to gross DTAs was \$186,957 for December 31, 2022. The Company bases its estimates of the future realization of DTAs primarily on historic taxable income and existing DTLs.

- D. The provision for federal income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference were as follows:

	12/31/2023	Effective Tax Rate	12/31/2022	Effective Tax Rate
Provision computed at statutory rate	\$ 4,836,674	21.0 %	\$ 2,348,547	21.0 %
Transfer pricing adjustment	(1,075,119)	(4.8)%	(921,693)	(8.2)%
Tax-exempt interest	(192,728)	(0.8)%	(400,083)	(3.6)%
Change in nonadmitted assets	(374,026)	(1.6)%	262,907	2.4 %
Prior year true-up	(8,765)	0.0 %	(6,952)	(0.1)%
Change in valuation allowance adjustment	16,695	0.1 %	186,957	1.7 %
Other	12	0.0 %	100,023	0.8 %
Total	<u>\$ 3,202,743</u>	<u>13.9 %</u>	<u>\$ 1,569,706</u>	<u>14.0 %</u>
Federal and foreign income taxes incurred	\$ 3,941,669	17.1 %	\$ 1,204,829	10.7 %
Change in net deferred income taxes	(738,926)	(3.2)%	364,877	3.3 %
Total statutory income taxes	<u>\$ 3,202,743</u>	<u>13.9 %</u>	<u>\$ 1,569,706</u>	<u>14.0 %</u>

The transfer pricing adjustment allows taxpayers to apply different methods to price current period intercompany services at arm's length prices (i.e., prices at which unrelated entities would be willing to transact), which results in a permanent deduction for tax reporting purposes.

E.

- (1) At December 31, 2023 and 2022, the Company had no net capital loss or net operating loss carryforwards for tax purposes.
- (2) The amount of federal income taxes incurred that is available for recoupment in the event of future net losses is as follows:

Year	Ordinary	Capital	Total
2023	\$ 4,174,783	\$ —	\$ 4,174,783
2022	462,261	—	462,261
2021	NA	180,674	180,674
Total	<u>\$ 4,637,044</u>	<u>\$ 180,674</u>	<u>\$ 4,817,718</u>

- (3) The Company did not report any deposits as admitted assets under Internal Revenue Code Section 6603 at December 31, 2023 and 2022.

F.

- (1) At December 31, 2023, the Company's Federal Income Tax Return was consolidated with the following entities:

@ Credentials Inc.	CVS CAREMARK INDEMNITY LTD.
ACCENDO INSURANCE COMPANY	CVS FOREIGN, INC.
ACS ACQCO CORP.	CVS Healthcare Practices of California
Active Health Management, Inc.	CVS Healthcare Practices of New Jersey LLC
Adminco, Inc.	CVS Healthcare Practices PLLC
Administrative Enterprises, Inc.	CVS INTERNATIONAL, INC.
ADVANCED CARE SCRIPTS, INC	CVS Medical Practices (KS) LLC
Aetna Better Health Inc. (Georgia)	CVS PHARMACY, INC.
Aetna Better Health Inc. (NJ)	CVS PR CENTER, INC.
Aetna Better Health Inc. (NY)	CVS RX SERVICES, INC.
Aetna Better Health Inc. (OH)	CVS WWRE, INC.
Aetna Better Health of California, Inc.	DELAWARE CVS PHARMACY, L.L.C.
Aetna Better Health of Florida, Inc. (F/K/A Coventry Health Care of Florida, Inc.)	Delaware Physicians Care, Inc.
Aetna Better Health of Illinois, Inc. (F/K/A IlliniCare Health Plan, Inc.)	E.T.B., INC.
Aetna Better Health of Indiana Inc.	Echo Merger Sub, Inc
Aetna Better Health of Kansas Inc.	ECKERD CORPORATION OF FLORIDA, INC.
Aetna Better Health of Kentucky Insurance Co.	First Health Group Corp.
Aetna Better Health of Michigan, Inc.	First Health Life and Health Insurance Company

NOTES TO FINANCIAL STATEMENTS

Aetna Better Health of Missouri LLC	Florida Health Plan Administrators, LLC
Aetna Better Health of Nevada Inc.	Gemini Health Holding, LLC
Aetna Better Health of North Carolina, Inc.	George Safran, M.D., P.C.
Aetna Better Health of Oklahoma Inc.	Group Dental Service of Maryland, Inc.
Aetna Better Health of Tennessee Inc. (F/K/A Aetna Better Health Inc. (TN))	Group Dental Service, Inc.
Aetna Better Health of Texas, Inc.	Halo Holdco I, Inc.
Aetna Better Health of Washington, Inc.	Halo Holdco II, Inc.
Aetna Better Health Premier Plan MMAI Inc. (f/n/a Aetna Better Health Inc. (IL))	Health and Human Resource Center, Inc.
Aetna Better Health, Inc. (Connecticut)	Health Data & Management Solutions, Inc.
Aetna Better Health, Inc. (LA)	Health Re, Inc.
Aetna Better Health, Inc. (PA)	HOLIDAY CVS, L.L.C.
Aetna Corporate Services LLC	IHS Acquisition XXX, Inc
Aetna Dental Inc. (New Jersey)	In Person, Virtual Medical Services PLLC
Aetna Dental Inc. (Texas)	IOWA CVS PHARMACY, L.L.C.
Aetna Dental of California, Inc.	KENTUCKY CVS PHARMACY, L.L.C.
Aetna Florida, Inc.	Managed Care Coordinators, Inc.
Aetna Health and Life Insurance Company	MARYLAND CVS PHARMACY, L.L.C.
Aetna Health Inc. (Connecticut)	MASSACHUSETTS CVS PHARMACY, INC.
Aetna Health Inc. (Florida)	MC Diagnostic of Connecticut, P.C.
Aetna Health Inc. (Georgia)	MELVILLE REALTY CO., INC.
Aetna Health Inc. (LA)	Mental Health Associates, Inc.
Aetna Health Inc. (Maine)	Mental Health Network of New York IPA, Inc.
Aetna Health Inc. (New Jersey)	Meritain Health, Inc.
Aetna Health Inc. (NY)	MHNet of Florida, Inc.
Aetna Health Inc. (Pennsylvania)	Minute Clinic Diagnostic of North Carolina, P.C.
Aetna Health Inc. (Texas)	MinuteClinic Diagnostic Medical Group of California, Inc.
Aetna Health Insurance Co	MinuteClinic Diagnostic Medical Group of Orange County, Inc.
Aetna Health Insurance Company of New York	MinuteClinic Diagnostic Medical Group of San Diego, Inc.
Aetna Health of California Inc.	MINUTECLINIC DIAGNOSTIC OF ILLINOIS, L.L.C.
Aetna Health of Iowa, Inc	MinuteClinic Diagnostic of Illinois, PLLC
Aetna Health of Michigan Inc. (F/K/A Aetna Health Inc. (Michigan))	MinuteClinic Diagnostic of Kansas, P.A.
Aetna Health of Ohio, Inc. (F/K/A Aetna Better Health of Iowa, Inc.)	MinuteClinic Diagnostic of Minnesota, P.A.
Aetna Health of Utah, Inc.	MinuteClinic Diagnostic of New Jersey, LLC
Aetna HealthAssurance Pennsylvania, Inc.	MinuteClinic Diagnostic of Tennessee, P.C.
Aetna Inc.	MinuteClinic Diagnostic of Washington, PLLC
Aetna Ireland Inc.	MinuteClinic Diagnostics of Indiana, LLC
Aetna Risk Assurance Company of Connecticut	MinuteClinic Diagnostics of Michigan, P.C.
Aetna Student Health Agency, Inc.	MinuteClinic Telehealth Services of Texas Association
ALABAMA CVS PHARMACY, L.L.C.	MinuteClinic Video Virtual Care North, LLC
American Health Holding, Inc.	MinuteClinic Video Virtual Care, PLLC
APRIA FINANCE HOLDINGS, INC.	Niagara Re, Inc.
APS Enterprises Holding Company, Inc	Noah HoldCo I, Inc.
AUSHC Holdings, Inc. (CT)	Noah HoldCo II, Inc.
Brookview Medical Associates, PLLC	North 53 TAOH Limited
BRUIN ACQUISITION CO., INC.	NORTH 53, LLC
Carefree Insurance Services, Inc.	NORTH CAROLINA CVS PHARMACY, L.L.C.
CAREMARK ULYSSES HOLDING CORP.	Oak Street Health Inc.
Claims Administration Corporation	Oak Street Health MSO LLC
Cofinity, Inc.	OKLAHOMA CVS PHARMACY, L.L.C.
CONNECTICUT CVS PHARMACY, L.L.C.	Parekh MinuteClinic of Nevada, P.C.
CORAM ALTERNATE SITE SERVICES, INC.	Performax, Inc.
CORAM HEALTHCARE CORPORATION OF ALABAMA	Pharm Plus Acquisition, Inc
CORAM HEALTHCARE CORPORATION OF FLORIDA	Precision Benefit Services, Inc.
CORAM HEALTHCARE CORPORATION OF GREATER D.C.	PrimeNet, Inc.
CORAM HEALTHCARE CORPORATION OF GREATER NEW YORK	Prodigy Health Group, Inc.
CORAM HEALTHCARE CORPORATION OF INDIANA	Professional Risk Management, Inc.
CORAM HEALTHCARE CORPORATION OF MASSACHUSETTS	Resources for Living, LLC
CORAM HEALTHCARE CORPORATION OF MISSISSIPPI	RETRAC, INC.
CORAM HEALTHCARE CORPORATION OF NEVADA	RICHMOND HEIGHTS ACQUISITION CORP.
CORAM HEALTHCARE CORPORATION OF NORTH TEXAS	Rubicon MD Inc
CORAM HEALTHCARE CORPORATION OF NORTHERN CALIFORNIA	RubiconMD Holdings Inc.
CORAM HEALTHCARE CORPORATION OF SOUTHERN CALIFORNIA	Schaller Anderson Medical Administrators Inc
CORAM HEALTHCARE CORPORATION OF SOUTHERN FLORIDA	Signify Health Medical Associates of California
CORAM HEALTHCARE CORPORATION OF UTAH	Signify Health Medical Associates of Kansas, LLC
Coventry Consumer Advantage, Inc.	Signify Health Medical Associates of New Jersey, LLC
Coventry Health and Life Insurance Company	Signify Health Medical Associates, PLLC
Coventry Health Care National Accounts, Inc.	Signify Health, Inc.

NOTES TO FINANCIAL STATEMENTS

Coventry Health Care National Network, Inc.	Signify NewCo, Inc.
Coventry Health Care of Illinois, Inc.	SILVERSCRIPT INSURANCE COMPANY
Coventry Health Care of Kansas, Inc.	SKY ACQUISITION LLC
Coventry Health Care of Missouri, Inc.	T2 MEDICAL, INC.
Coventry Health Care of Nebraska, Inc.	TENNESSEE CVS PHARMACY, L.L.C.
Coventry Health Care of Virginia, Inc.	The Vasquez Group, Inc.
Coventry Health Care of West Virginia, Inc.	U.S. Health Care Properties, Inc.
Coventry Health Plan of Florida, Inc.	UAC HOLDING, INC.
Coventry HealthCare Management Corporation	US Bioservices Corporation
Coventry Prescription Management Services, Inc.	VIRGINIA CVS PHARMACY, L.L.C.
CVS Accountable Care Organization Inc.	Work & Family Benefits, Inc.
CVS AOC Corporation	Zinc Health Ventures, LLC
CVS ARCLIGHT, INC.	

(2) As explained in Note 1, the Company participates in a tax sharing agreement with its parent and affiliates.

- G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.
- H. The Company was not subject to the Repatriation Transition Tax at December 31, 2023 and 2022.
- I. The Company did not recognize any gross Alternative Minimum Tax credit at December 31, 2023 and 2022.

The CVS Health consolidated U.S. Federal income tax return filing group, of which the Company is a member, meets the average “adjusted financial statement income” threshold and is required to perform Corporate Alternative Minimum Tax (“CAMT”) calculations in 2023. The amount of CAMT payable (expense) or CAMT credit DTA is recognized in accordance with a tax sharing agreement between CVS Health and the Company which is consistent with SSAP No. 101. As of December 31, 2023, the Company has determined that it does not expect to be liable for CAMT in 2023 and did not recognize any CAMT credit DTA.

10. Information Concerning Parent, Subsidiaries, Affiliates, and Other Related Parties

A. and B.:

Transactions occurring between the Company and its parent, subsidiaries and affiliates excluding reinsurance transactions and non-insurance transactions involving less than ½ of 1% of the Company’s total admitted assets and cost allocation transactions follow:

December 31, 2023

Date of transaction	Explanation of transaction	Name of reporting entity	Name of affiliate	Assets received by insurer		Assets transferred by insurer	
				Statement value	Statement description	Statement value	Statement description
May 30, 2023	Ordinary Dividend	Aetna Health Inc. (a New Jersey corporation)	Aetna Health Holdings, LLC			\$ 10,000,000	Cash

The Company did not have any transactions during 2022 with its parent, subsidiaries and affiliates excluding reinsurance transactions and non-insurance transactions involving less than ½ of 1% of the Company’s total admitted assets, and cost allocation transactions.

- C. The Company did not have any transactions with related parties who are not reported on Schedule Y at December 31, 2023.
- D. At December 31, 2023 and 2022, the Company had the following amounts due to and due from affiliates, which exclude amounts related to pharmacy rebate transactions as discussed more fully in Note 28 and the Company's reinsurance agreements if applicable.

	December 31,	
	2023	2022
Amounts due to affiliates		
Aetna Health Management, LLC	\$ 8,191,665	\$ 9,243,146
Aetna Health Insurance Company	\$ —	\$ 4,000
Total due to affiliates	\$ 8,191,665	\$ 9,247,146

At December 31, 2023 and 2022, the Company had no amounts due from affiliates.

The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter.

- E. As of and for the years ended December 31, 2023 and 2022, the Company had the following significant transactions with affiliates:

The Company and Aetna Health Management, LLC (“AHM”) are parties to an administrative services agreement, under which AHM provides certain administrative services, which include but are not limited to, accounting and processing of

NOTES TO FINANCIAL STATEMENTS

premiums and claims. Under this agreement, the Company remits a percentage of its earned commercial and Medicare premium revenue, as applicable, to AHM as a fee, subject to an annual true up mechanism as defined in the agreement. Under the agreement, this true-up is due to be settled with the affiliate by April 15th of the following contract year (which is January 1 to December 31 annually). The terms of settlement require that these amounts be settled within 45 days after the end of the calendar quarter. For these services, the Company was charged \$68,934,473 and \$63,590,305 in 2023 and 2022, respectively.

The agreement with AHM also enables the Company to receive manufacturers' pharmacy rebates from Caremark-PCS Health, LLC, an affiliate, to deliver pharmacy benefit management services to the Company via AHM. The Company earned pharmaceutical rebates of \$25,945,929 and \$27,881,129, which were recorded as a reduction of medical costs, in 2023 and 2022, respectively.

These agreements also provide for interest on all intercompany balances. Interest earned on amounts due from affiliates was \$202,706 in 2023 and \$79,637 in 2022. Interest incurred on amounts due to affiliates was \$435,021 in 2023 and \$161,354 in 2022.

The Company has an insolvency agreement with Aetna Health Insurance Company ("AHIC"), a wholly-owned subsidiary of Aetna. This agreement provides that in the event that the Company ceases operations or becomes insolvent, AHIC will continue to pay benefits for any members confined as inpatients on the date of insolvency until their discharge. This agreement also provides that AHIC will continue benefits for any member until the end of the contract period for which premium has been paid, but for no longer than thirty-one days. AHIC will also make available to members, for a period of thirty-one days, replacement insurance policies.

As explained in Note 1, Aetna and its wholly-owned subsidiaries, including the Company, participate in a tax sharing agreement with CVS Health. All federal income tax receivables/payables are due from/due to CVS Health.

- F. At December 31, 2023, the Company has a guarantor agreement with Aetna. The agreement provides that in the event of the Company's insolvency, Aetna will pay all expenses and claims incurred by the Company during insolvency pursuant to the obligation with employer groups and subscribers until the end of the subscription contract period for which premiums have been received.
- G. All outstanding shares of the Company are owned by Aetna Health Holdings, LLC, whose ultimate parent is CVS Health.
- H. At December 31, 2023, the Company did not own shares of an upstream intermediate entity or CVS Health, either directly or indirectly.
- I. At December 31, 2023, the Company did not hold any investments in any subsidiary, controlled or affiliated ("SCA") entity that exceeded 10% of the Company's admitted assets.
- J. At December 31, 2023, the Company did not hold any investments in any impaired SCA entity.
- K. At December 31, 2023, the Company did not hold any investments in any foreign insurance subsidiaries.
- L. At December 31, 2023, the Company did not hold any investments in a downstream noninsurance holding company.
- M. At December 31, 2023, the Company did not have any SCA investments.
- N. At December 31, 2023, the Company did not have any investments in an insurance SCA.
- O. The Company did not have any SCA or SSAP No. 48 entity investments where the Company's share of losses in the SCA exceeds its investment in the SCA.

11. Debt

- A. The Company did not have any items related to debt, including capital notes at December 31, 2023.
- B. The Company did not have any Federal Home Loan Bank agreements at December 31, 2023.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

- A.- I. The Company did not have a retirement plan, deferred compensation plan, or other postretirement benefit plan at December 31, 2023 or 2022.

13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

- A. The Company had 200 shares of common capital stock authorized, issued and outstanding with a par value of \$1 per share at December 31, 2023 and 2022.
- B. The Company had no shares of preferred stock issued and outstanding at December 31, 2023 and 2022.
- C. Dividend Restrictions

NOTES TO FINANCIAL STATEMENTS

Under the laws of the State of New Jersey, the Company shall not pay out dividends without the prior written approval of the New Jersey Department. The New Jersey Department may disapprove the dividend request for a period of 30 days after the receipt of notification.

Pursuant to New Jersey statute, no domestic insurer shall pay an extraordinary distribution to its shareholders until: (a) thirty days after the New Jersey Department has received notice of the declaration thereof and has not within such period disapproved such payment, or (b) the New Jersey Department approves such payment within the 30-day period. An extraordinary dividend or distribution is any dividend or distribution of cash or other property, whose fair market value together with that of other dividends or distributions made within the preceding twelve months exceeds the greater of: (a) 10% of the Company's surplus as regards to policyholders as of the 31st day of December next preceding, or (b) the net income, not including realized gains, for the 12 month period ending the 31st day of December next preceding, but shall not include pro rata distributions of any class of the Company's own securities.

- D. The Company paid \$10,000,000 as an ordinary dividend to its parent on May 30, 2023. The Company did not pay any dividends in 2022.
- E. Within the limitations of (C) above, there are no other restrictions placed on the portion of the Company profits that may be paid as ordinary dividends to stockholders.
- F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.
- G. The Company had no advances to surplus not repaid.
- H. The Company did not hold any stock for any special purposes at December 31, 2023 or 2022.
- I. There were no changes in the balances of special surplus funds from the prior year.
- J. At December 31, 2023, there was -\$790,505 of unassigned funds that was represented or reduced by unrealized gains and losses.
- K. The Company has not issued any surplus notes or debentures or similar obligations at December 31, 2023 or 2022.
- L. The Company did not participate in any quasi-reorganizations during the statement year.
- M. The Company did not participate in any quasi-reorganizations in the past 10 years.

14. Liabilities, Contingencies and Assessments

- A. The Company did not have any contingent commitments at December 31, 2023 or 2022.
- B. Assessments

Guaranty Fund Assessments

(1) Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company's assessments generally are based on a formula relating to the Company's health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payers such as not-for-profit consumer-governed health plans established under the ACA.

The Company did not have any contingent assessments at December 31, 2023 or 2022.

- C. The Company did not have any gain contingencies at December 31, 2023 or 2022.
- D. The Company did not have any claims related extra contractual obligation and bad faith losses stemming from lawsuits at December 31, 2023 or 2022.
- E. The Company did not have any joint and several liability arrangements at December 31, 2023 or 2022.
- F. Various liabilities arise in the normal course of the Company's business and have been recorded. In the opinion of management, any ultimate contingent losses will not have a material adverse effect on the Company's future results of operations and financial position. The Company, to the best of its knowledge, has no assets that it considers impaired that are not already recorded in the Company's books.

The Company maintains insurance coverage for certain litigation exposures in an amount it believes is reasonable.

15. Leases

The Company did not have any material lease obligations at December 31, 2023 or 2022.

NOTES TO FINANCIAL STATEMENTS

16. Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk

The Company did not have any financial instruments with off-balance sheet risk or financial instruments with concentrations of credit risk at December 31, 2023 or 2022.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

The Company did not have any transfers of receivables reported as sales for the years ending December 31, 2023 or 2022.

B. Transfer and Servicing of Financial Assets

(1) The Company did not have any loaned securities at December 31, 2023 or 2022.

(2) and (3):

The Company did not have any servicing assets or liabilities at December 31, 2023 or 2022.

(4) The Company did not have any securitized financial assets at December 31, 2023 or 2022.

(5) The Company did not have any transfers of financial assets accounted for as secured borrowing at December 31, 2023 or 2022.

(6) The Company did not have any transfers of receivables with recourse at December 31, 2023 or 2022.

(7) The Company did not have any dollar repurchase or reverse repurchase agreements at December 31, 2023 or 2022.

C. Wash Sales

(1) In the course of the Company's asset management, securities are sold and reacquired within 30 days of the sale date to enhance the Company's yield on its investment portfolio.

(2) The Company had no securities sold during the year for the year ended December 31, 2023 and reacquired within 30 days of the sale date.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. The Company did not serve as an Administrative Services Only ("ASO") plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2023.

B. The Company did not serve as an Administrative Services Contract plan administrator for uninsured accident and health plans or the uninsured portion of partially insured plans for the period ended December 31, 2023.

C. Medicare or Similarly Structured Cost Based Reimbursement Contract:

(1) Revenue from the Company's Medicare (or similarly structured cost based reimbursement contract) contract for the year 2023 was \$485,918,031.

(2) As of December 31, 2023, the Company has recorded receivables from the following payors whose account balances are greater than 10% of the Company's amounts receivable from uninsured accident and health plans or \$10,000:

Centers for Medicare and Medicaid Services	\$2,988,150
--	-------------

(3) In connection with the Company's Medicare (or similarly structured cost based reimbursement contract) contract, the Company has recorded allowance and reserves for adjustment of recorded revenues as and if applicable.

(4) CMS periodically perform audits of Medicare revenue and may seek return of premium payments made to the Company if risk adjustment factors are not properly supported by medical record data. The Company estimates and records reserves for CMS audits based on information available at the time the estimates are made. Although the Company believes it maintains appropriate reserves for its exposure to the CMS audits, actual results could differ materially from those estimates.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company did not have any material direct premiums written through/produced by managing general agents or third party administrators for the years ended December 31, 2023 and 2022.

20. Fair Value Measurements

A.

NOTES TO FINANCIAL STATEMENTS

- (1) The Company had no material assets and liabilities that are measured and reported at fair value in the financial statements as of December 31, 2023 and 2022.
- (2) There were no material realized and unrealized capital gains, purchases, sales, settlements, or transfers into or out of the Company's Level 3 financial assets during 2023 or 2022.
- (3) Transfers in and out of all levels are recognized at the end of the reporting period of which the transfer occurred.
- (4) The Company's fair value measurement valuation techniques are described in B. below.
- (5) The Company did not have any derivative instruments at December 31, 2023 or 2022.

B. The fair values of the Company's financial instruments are based on valuations that include inputs that can be classified within one of three levels of a hierarchy. The following are the levels of the hierarchy and a brief description of the type of valuation information ("inputs") that qualifies a financial asset or liability for each level:

- **Level 1** - Unadjusted quoted prices for identical assets or liabilities in active markets.
- **Level 2** - Inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, inputs that are observable that are not prices (such as interest rates and credit risks) and inputs that are derived from or corroborated by observable markets.
- **Level 3** - Developed from unobservable data, reflecting the Company's own assumptions.

Financial assets and liabilities are classified based upon the lowest level of input that is significant to the valuation. When quoted prices in active markets for identical assets and liabilities are available, the Company uses these quoted market prices to determine the fair value of financial assets and liabilities and classifies these assets and liabilities as Level 1. In other cases where a quoted market price for identical assets and liabilities in an active market is either not available or not observable, the Company estimates fair value using valuation methodologies based on available and observable market information or by using a matrix pricing model. These financial assets and liabilities would then be classified as Level 2. If quoted market prices are not available, the Company determines fair value using broker quotes or an internal analysis of each investment's financial performance and cash flow projections. Thus, financial assets and liabilities may be classified in Level 3 even though there may be some significant inputs that may be observable.

C. The carrying values and estimated fair values of the Company's financial instruments at December 31, 2023 and 2022 were as follows:

December 31, 2023

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	\$211,250,292	\$214,487,694	\$ 57,320,766	\$153,929,526	\$ —	\$ —	\$ —

December 31, 2022

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds, short-term investments and cash equivalents	\$205,944,369	\$215,916,938	\$ 48,115,382	\$157,828,987	\$ —	\$ —	\$ —

In evaluating the Company's management of interest rate and liquidity risk and currency exposures, the fair values of all assets and liabilities should be taken into consideration, not only those presented above.

- D. The Company did not have any financial instruments where it was not practicable to estimate the fair value.
- E. The Company has not elected to use the net asset value practical expedient to fair value to measure its investments.

21. Other Items

A. Unusual or Infrequent Items

The Company did not have any unusual or infrequent items for the years ended December 31, 2023 and 2022

B. Troubled Debt Restructuring

The Company did not have any troubled debt restructuring in the years ended December 31, 2023 and 2022.

C. Other Disclosures

Minimum Capital and Surplus

NOTES TO FINANCIAL STATEMENTS

Under the laws of the State of New Jersey, the Company is required to maintain a minimum capital and surplus equal to the greater of (1) \$1,000,000 adjusted annually by the Consumer Price Index; (2) 2% of the annual premium revenues as reported by the Company on its most recent annual financial statement filed with the Commissioner of Health and Commissioner of Banking and Insurance for the first \$150,000,000 of premium reported and 1% of the annual premium in excess of the first \$150,000,000 of premium reported; (3) an amount equal to the sum of three months of uncovered health care expenditures; or (4) an amount equal to the sum of 8% of the annual health care expenditures (not including those expenditures paid on a capitated basis and those made on a managed hospital payment basis) plus 4% of the annual hospital expenditures paid on a managed hospital payment basis. At December 31, 2023 and 2022, the Company's capital and surplus exceeded all such requirements.

The NAIC utilizes risk-based capital ("RBC") standards for health organizations, including HMOs, that are designed to identify weakly capitalized companies by comparing each company's adjusted capital and surplus to its required capital and surplus (the "RBC Ratio"). The RBC Ratio is designed to reflect the risk profile of a company. Within certain ratio ranges, regulators have increasing authority to take action as the RBC Ratio decreases. There are four levels of regulatory action, ranging from requiring insurers to submit a comprehensive plan to the state insurance commissioner to requiring the state insurance commissioner to place the insurer under regulatory control. At December 31, 2023 and 2022, the Company had capital and surplus that exceeded the level that would require regulatory action.

COVID-19

The public health emergency related to the Coronavirus Disease 2019 ("COVID-19") pandemic expired in May 2023, however COVID-19 still exists and it may, like many other respiratory viruses, wax and wane depending on geography and seasonality. The future impact COVID-19 will have on the Company and its ability to accurately forecast health care and other benefit costs is uncertain, and will depend on the geographies impacted, whether new variants emerge and their severity, the availability and costs of testing, vaccination and treatment, and legal and regulatory actions. COVID-19 may also impact provider behavior, utilization trends, membership, and overall economic conditions. Those primary drivers are beyond the Company's knowledge and control. As a result, the impact COVID-19 will have on the Company's businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material.

Health Care Reform

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010's (collectively, the "ACA") made broad-based changes to the United States health care system. In June 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety and issued an opinion preserving the ACA and its consumer protections in its current form. Even though the ACA was deemed constitutional, there may nevertheless be continued efforts to invalidate, modify, repeal or replace portions of it. In addition to litigation, parts of the ACA continue to evolve through the promulgation of executive orders, legislation, regulations and guidance at the federal or state level. The Company expects the ACA, including potential changes thereto, to continue to significantly impact its business operations and operating results, including pricing, medical benefit ratios ("MBRs") and the geographies in which the Company's products are available.

Medicare

The Company's Medicare Advantage products are heavily regulated by CMS. The regulations and contractual requirements applicable to the Company and other private participants in Medicare programs are complex, expensive to comply with and subject to change. For example, in the second quarter of 2014, CMS issued a final rule implementing the ACA requirements that Medicare Advantage plans report and refund to CMS overpayments that those plans receive from CMS. The precise interpretation, impact and legality of this rule are not clear and are subject to pending litigation. Payments the Company receives from CMS for its Medicare Advantage business also are subject to risk adjustment based on the health status of the individuals enrolled. Elements of that risk adjustment mechanism continue to be challenged by the U.S. Department of Justice, the Office of Inspector General of the HHS (the "OIG") and CMS itself. Substantial changes in the risk adjustment mechanism, including changes that result from enforcement or audit actions, could materially affect the amount of the Company's Medicare reimbursement, require the Company to raise prices or reduce the benefits offered to Medicare beneficiaries, and potentially limit the Company's (and the industry's) participation in the Medicare program.

The Company has invested significant resources to comply with Medicare standards, and its Medicare compliance efforts will continue to require significant resources. CMS may seek premium and other refunds, prohibit the Company from continuing to market and/or enroll members in or refuse to passively enroll members in one or more of the Company's Medicare or Medicare-Medicaid demonstration (historically known as "dual eligible") plans, exclude the Company from participating in one or more Medicare, dual eligible or dual eligible special needs plan programs and/or institute other sanctions and/or civil monetary penalties against the Company if it fails to comply with CMS regulations or its Medicare contractual requirements.

A portion of each Medicare Advantage plan's reimbursement is tied to the plan's "star ratings." The star rating system considers a variety of measures adopted by CMS, including quality of preventative services, chronic illness management, compliance and overall customer satisfaction. Only Medicare Advantage plans with an overall star rating of 4 or more stars (out of 5 stars) are eligible for a quality bonus in their basic premium rates. The Company's Medicare contract star rating for 2023 did not reach 4 or more stars, and this decrease in the star rating will mean that the Company will no longer be eligible for CMS' quality bonus payments in 2024, though efforts to partially mitigate certain adverse impacts associated with the decrease in the star rating have received regulatory approval. CMS also gives PDP's star ratings that affect each PDP's enrollment. Medicare Advantage and PDP plans that are rated less than 3 stars for three consecutive years are subject to contract termination by CMS. CMS continues to revise its star ratings system to make it harder to achieve 4 or more stars. There can be no assurances that the Company will be successful in maintaining or improving its star ratings in future years.

NOTES TO FINANCIAL STATEMENTS

Accordingly, the Company's Medicare Advantage plans may not continue to be or become eligible for full level quality bonuses, which could adversely affect the benefits such plans can offer, reduce membership and/or reduce profit margins.

Federal Employees Health Benefits Program

The Company contracts with the OPM to provide managed health care services under the FEHB program in its service areas. These contracts with the OPM and applicable government regulations establish premium rating arrangements for this program. OPM regulations require that community-rated FEHB plans meet a FEHB program-specific minimum MLR by plan code and market. Managing to these rules is complicated by the simultaneous application of the minimum MLR standards and associated premium rebate requirements of the ACA. The OPM also is auditing the Company and its other contractors to, among other things, verify that plans meet their applicable FEHB program-specific MLR and the premiums established under the OPM's Insured contracts and costs allocated pursuant to the OPM's cost-based contracts are in compliance with the requirements of the applicable FEHB program. The OPM may seek premium refunds or institute other sanctions against the Company if the Company fails to comply with the FEHB program requirements.

- D. The Company did not have any business interruption insurance recoveries for the years ending December 31, 2023 or 2022.
- E. The Company did not have any state transferable and non-transferable tax credits for the years ending December 31, 2023 or 2022.
- F. The Company did not have any subprime mortgage related risk exposures at December 31, 2023 or 2022.
- G. The Company did not have any retained assets at December 31, 2023 or 2022.
- H. The Company did not have any insurance-linked securities contracts at December 31, 2023 or 2022.
- I. The Company did not have amounts that could be realized on life insurance at December 31, 2023 or 2022.

22. Events Subsequent

Type I - Recognized Subsequent Events

Subsequent events have been considered through February 29, 2024 for the statutory statement issued on February 29, 2024.

The Company had no known reportable recognized subsequent events.

Type II - Nonrecognized Subsequent Events

Subsequent events have been considered through February 29, 2024 for the statutory statement issued on February 29, 2024.

The Company had no known reportable nonrecognized subsequent events.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 – General Interrogatories

- (1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes () No (X)

If yes, give full details. N/A

- (2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 – Ceded Reinsurance Report – Part A

- (1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than nonpayment of premium or other similar credit?

Yes () No (X)

- a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary,

NOTES TO FINANCIAL STATEMENTS

the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate. N/A.

- b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability for these agreements in this statement? N/A.
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details. N/A

Section 3 – Ceded Reinsurance Report – Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the insurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. N/A.
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes () No (X)

If yes, what is the amount of reinsurance credit, whether an asset or a reduction of liability, taken for such new agreements or amendments? N/A.

- B. The Company did not have uncollectible reinsurance at December 31, 2023 or 2022.
- C. The Company did not have any commutation of ceded reinsurance at December 31, 2023 or 2022.
- D. The Company's certified reinsurer's rating has not been downgraded or its status subject to revocation at December 31, 2023 or 2022.
- E. The Company had no reinsurance contracts to which the reinsurance credit disclosure applies at December 31, 2023.

24. Retrospectively Rated Contracts and Contracts Subject to Redetermination

- A. Through annual contracts with CMS, the Company's Medicare Advantage revenues ultimately received for each member are based on that member's health status and demographic characteristics, as determined via the CMS risk adjustment process, under which the Company regularly submits risk adjustment data to CMS. Under the risk adjustment process, the Company records a receivable for future revenues that it expects to receive from CMS in the following year, after the final reconciliation of risk adjustment data for the current contract year is complete. These amounts are recognized in the current year as premiums under contracts subject to redetermination. In addition, the Company's Medicare Advantage contracts are subject to retrospective rating provisions under which the Company and CMS share in amounts above and below agreed-upon target medical benefit ratios.

Premium revenue subject to the minimum MLR rebate requirements of the ACA is recorded net of the estimated minimum MLR rebates for the current calendar year. The Company estimates the minimum MLR rebates by projecting MLRs for certain markets, as defined by the ACA, for each state in which the Company operates. The claims and premiums used in estimating such rebates are modified for certain adjustments allowed by the ACA and include a statistical credibility adjustment for those states with a number of members that is not statistically credible.

- B. Accrued retrospective premiums are recorded as an adjustment to earned premiums and are estimated based on calculations that compare the Company's expected financial results for the contract against the appropriate medical benefit ratio target.

C. Contracts Subject to Retrospective Rating Features

The Company had net premiums written of \$511,246,083 that were subject to retrospective rating features for the year ending December 31, 2023 representing 100% of total net premiums written.

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

NOTES TO FINANCIAL STATEMENTS

	1 Individual	2 Small Group Employer	3 Large Group Employer	4 Other Categories with rebates	5 Total
Prior Reporting Year					
(1) Medical Loss Ratio Rebates Incurred	—	—	280,875	—	280,875
(2) Medical Loss Ratio Rebates Paid	—	—	—	—	—
(3) Medical Loss Ratio Rebates Unpaid	—	—	280,875	—	280,875
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	—
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	—
(6) Rebates Unpaid net of reinsurance	XXX	XXX	XXX	XXX	280,875
Current Reporting Year-to-Date					
(1) Medical Loss Ratio Rebates Incurred	—	—	1,792,013	—	1,792,013
(2) Medical Loss Ratio Rebates Paid	—	—	711,096	—	711,096
(3) Medical Loss Ratio Rebates Unpaid	—	—	1,361,792	—	1,361,792
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	—
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	—
(6) Rebates Unpaid net of reinsurance	XXX	XXX	XXX	XXX	1,361,792

E. Risk Sharing Provisions of the Affordable Care Act ("ACA")

(1) Did the reporting entity write accident and health insurance premium which is subject to the ACA risk sharing provisions (YES/NO)? Yes No

(2) through (5): Not applicable.

25. Change in Incurred Claims and Claims Adjustment Expense

The following table shows the components of the change in claims unpaid, unpaid claims adjustment expense and aggregate health claim reserves for the years ended December 31, 2023 and 2022.

	2023	2022
Balance, January 1	\$ 57,783,736	\$ 60,966,337
Health care receivable	(3,610,913)	(3,472,445)
Balance, January 1, net of health care receivable	54,172,823	57,493,892
Incurred related to:		
Current year	434,504,219	468,725,336
Prior years	1,714,742	(2,186,913)
Total incurred	436,218,961	466,538,423
Paid related to:		
Current year	383,823,309	414,664,989
Prior years	56,300,955	55,194,503
Total paid	440,124,264	469,859,492
Balance, December 31, net of health care receivable	50,267,520	54,172,823
Health care receivable	3,384,007	3,610,913
Balance, December 31	<u>\$ 53,651,527</u>	<u>\$ 57,783,736</u>

A. Reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years increased by \$1,714,742 in 2023. Changes in prior periods' estimates represents the effect of unfavorable development of prior period health care cost estimates on current year net income, at each financial statement date. The unfavorable development of these reserves is primarily a result of the actual claim submission times for health care claims being longer than the Company had anticipated, as well as higher than expected health care cost trends in determining claims unpaid at prior financial statement date for 2023. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. Included in this increase, the Company experienced \$2,570,115 of unfavorable prior year claim development on retrospectively rated policies. However the business to which it relates is subject to premium adjustments.

Reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years decreased by \$2,186,913 in 2022. Changes in prior periods' estimates represents the effect of favorable development of prior period health care cost estimates on current year net income, at each financial statement date. The favorable development of these reserves is primarily a result of the actual claim submission times for health care claims being shorter than the Company had anticipated, as well as lower than expected health care cost trends in determining claims unpaid at prior financial statement date for 2022. Original estimates are increased or decreased, as additional information becomes known regarding individual claims.

NOTES TO FINANCIAL STATEMENTS

- B. There has been no significant change in the Company's methodologies and assumptions used in calculating the liability for unpaid claims and claim adjustment expenses.

26. Intercompany Pooling Arrangements

The Company did not have any intercompany pooling arrangements at December 31, 2023 or 2022.

27. Structured Settlements

The Company did not have any structured settlements at December 31, 2023 or 2022.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

The Company receives pharmaceutical rebates through an agreement with AHM. AHM has contractual agreements with CVS Caremark for rebates, which cover the Company's membership as well as the membership of other affiliates. The Company receives those rebates from AHM that relate to the Company's membership. The Company estimates pharmaceutical rebate receivables based upon the historical payment trends, actual utilization and other variables. Actual rebates collected are applied to the collection periods below, using a first in first out methodology. At December 31, 2023 and 2022, the Company had pharmaceutical rebate receivables of \$2,266,311 and \$2,189,887, respectively (refer to the Company's accounting practices related to pharmaceutical rebate receivables in Note 1).

The following table discloses the quarterly revenue and subsequent cash collections relating to the pharmaceutical rebates discussed in Note 10:

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2023	\$ 6,389,908	\$ —	\$ 4,218,467 ¹	\$ —	\$ —
9/30/2023	6,428,186	6,319,835	6,329,969	—	—
6/30/2023	6,538,745	6,560,892	6,575,926	—	—
3/31/2023	6,356,348	6,361,079	6,371,353	—	—
12/31/2022	7,023,364	7,188,711	7,199,036	—	—
9/30/2022	7,305,849	7,112,870	7,115,211	—	—
6/30/2022	7,270,975	6,993,120	6,989,500	—	—
3/31/2022	7,161,198	6,783,689	6,778,191	—	—
12/31/2021	7,747,857	7,673,404	7,639,974	—	—
9/30/2021	7,804,132	7,571,489	7,564,410	—	—
6/30/2021	8,009,932	8,154,918	8,149,234	—	—
3/31/2021	7,572,652	7,578,619	7,567,719	—	—

¹ Represents a portion of the estimated rebates for the quarter ending December 31, 2023, which were paid by AHM to the Company prior to December 31, 2023 and invoicing in 2024.

B. Risk sharing receivables

The Company did not have any admitted risk sharing receivables at December 31, 2023 or 2022.

Other receivables

Pharmacy Direct and Indirect Remuneration ("DIR") Generic

The Company receives retrospective generic performance network rebates ("PNR") on its Medicare business through an agreement with AHM. AHM has contractual agreements with network pharmacies for PNR. The PNR is performance based upon whether the participating pharmacies have met certain pre-established rates specified in the contract. The PNR is calculated by multiplying the applicable claims with a variable network rate based on the actual performance. The PNR receivables fit the category of other health care receivables per SSAP No. 84 - *Health Care and Government Insured Plan Receivables*.

Pharmacy DIR Brand

The Company receives retrospective brand PNR on its Medicare business through an agreement with AHM. As mentioned above, AHM has contractual agreements with network pharmacies for PNR. The program collects varying percentages of brand ingredient cost from pharmacies, depending how well they perform on adherence measures, including stars-related measures. The PNR agreement for 2020 has three performance measurement periods ending April 30, August 31 and December 31, respectively. The PNR receivables fit the category of other health care receivables per SSAP No. 84 - *Health Care and Government Insured Plan Receivables*.

NOTES TO FINANCIAL STATEMENTS

29. Participating Policies

The Company did not have any participating policies at December 31, 2023 or 2022.

30. Premium Deficiency Reserves

	<u>December 31, 2022</u>
1. Liability carried for premium deficiency reserves	\$0
2. Date of the most recent evaluation of this liability	12/31/2023
3. Was anticipated investment income utilized in the calculation?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>

31. Anticipated Salvage and Subrogation

The Company did not reduce its liability for unpaid claims/losses by any estimated anticipated salvage and subrogation at December 31, 2023 or 2022 as the Company records salvage and subrogation on a paid basis when cash is received.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

- 1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? Yes [X] No []
If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.
- 1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations? Yes [X] No [] N/A []
- 1.3 State Regulating? New Jersey
- 1.4 Is the reporting entity publicly traded or a member of a publicly traded group? Yes [X] No []
- 1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group. 0000064803
- 2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity? Yes [] No [X]
- 2.2 If yes, date of change:
- 3.1 State as of what date the latest financial examination of the reporting entity was made or is being made. 12/31/2020
- 3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 12/31/2020
- 3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). 06/28/2022
- 3.4 By what department or departments?
New Jersey Department of Banking and Insurance
- 3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments? Yes [] No [] N/A [X]
- 3.6 Have all of the recommendations within the latest financial examination report been complied with? Yes [] No [] N/A [X]
- 4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.11 sales of new business? Yes [] No [X]
4.12 renewals? Yes [] No [X]
- 4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:
4.21 sales of new business? Yes [] No [X]
4.22 renewals? Yes [] No [X]
- 5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? Yes [] No [X]
If yes, complete and file the merger history data file with the NAIC.
- 5.2 If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile

- 6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? Yes [] No [X]
- 6.2 If yes, give full information:
- 7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? Yes [] No [X]
- 7.2 If yes,
7.21 State the percentage of foreign control; 0.0 %
7.22 State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, government, manager or attorney-in-fact).

1 Nationality	2 Type of Entity

GENERAL INTERROGATORIES

- 8.1 Is the company a subsidiary of a depository institution holding company (DIHC) or a DIHC itself, regulated by the Federal Reserve Board? Yes [] No [X]
- 8.2 If the response to 8.1 is yes, please identify the name of the DIHC.
.....
- 8.3 Is the company affiliated with one or more banks, thrifts or securities firms? Yes [] No [X]
- 8.4 If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC

- 8.5 Is the reporting entity a depository institution holding company with significant insurance operations as defined by the Board of Governors of Federal Reserve System or a subsidiary of the depository institution holding company? Yes [] No [X]
- 8.6 If response to 8.5 is no, is the reporting entity a company or subsidiary of a company that has otherwise been made subject to the Federal Reserve Board's capital rule? Yes [] No [X] N/A []
- 9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?
Ernst & Young LLP; One Manhattan West; New York, NY 10001
- 10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation? Yes [] No [X]
- 10.2 If the response to 10.1 is yes, provide information related to this exemption:
.....
- 10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? Yes [] No [X]
- 10.4 If the response to 10.3 is yes, provide information related to this exemption:
.....
- 10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws? Yes [X] No [] N/A []
- 10.6 If the response to 10.5 is no or n/a, please explain.
.....
- 11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?
Jeffrey J.Drzazgowski, F.S.A., M.A.A.A.; CVS; 151 Farmington Ave., RE52; Hartford, CT 06156; Appointed Actuary
- 12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly? Yes [] No [X]
 - 12.11 Name of real estate holding company ...
 - 12.12 Number of parcels involved 0
 - 12.13 Total book/adjusted carrying value \$0
- 12.2 If yes, provide explanation
.....
- 13. **FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:**
- 13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?
N/A
- 13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located? Yes [] No []
- 13.3 Have there been any changes made to any of the trust indentures during the year? Yes [] No []
- 13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? Yes [] No [] N/A []
- 14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards? Yes [X] No []
 - a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
 - b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;
 - c. Compliance with applicable governmental laws, rules and regulations;
 - d. The prompt internal reporting of violations to an appropriate person or persons identified in the code; and
 - e. Accountability for adherence to the code.
- 14.11 If the response to 14.1 is No, please explain:
.....
- 14.2 Has the code of ethics for senior managers been amended? Yes [X] No []
- 14.21 If the response to 14.2 is yes, provide information related to amendment(s).
Improved language, branding, and formatting throughout the document, relocated sections, modified language to direct colleagues to the appropriate resource for questions, added language to clarify colleague reporting requirements, inserted language to emphasize the importance of only using and disclosing the minimum necessary amount of personal information, refreshed Q&As/examples, updated contact information, inserted language to emphasize that colleagues should not use proprietary and confidential business information of a former employer, revised language to align with policy language and policy updates, updated information related to the handling of Ethics Line reports, revised language to expand upon how CVS Health participates in Medicare programs, created stand-alone Medicaid Compliance section, and other minor updates throughout.
- 14.3 Have any provisions of the code of ethics been waived for any of the specified officers? Yes [] No [X]
- 14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).
.....

GENERAL INTERROGATORIES

- 15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? Yes [] No [X]
- 15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount

BOARD OF DIRECTORS

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Yes [X] No []
17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Yes [X] No []
18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? Yes [X] No []

FINANCIAL

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Yes [] No [X]
- 20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.11 To directors or other officers.....\$0
 - 20.12 To stockholders not officers.....\$0
 - 20.13 Trustees, supreme or grand (Fraternal Only)\$0
- 20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans):
- 20.21 To directors or other officers.....\$0
 - 20.22 To stockholders not officers.....\$0
 - 20.23 Trustees, supreme or grand (Fraternal Only)\$0
- 21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? Yes [] No [X]
- 21.2 If yes, state the amount thereof at December 31 of the current year:
- 21.21 Rented from others.....\$0
 - 21.22 Borrowed from others.....\$0
 - 21.23 Leased from others\$0
 - 21.24 Other\$0
- 22.1 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? Yes [X] No []
- 22.2 If answer is yes:
- 22.21 Amount paid as losses or risk adjustment \$0
 - 22.22 Amount paid as expenses\$ (48,046)
 - 22.23 Other amounts paid\$0
- 23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [] No [X]
- 23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount:\$0
- 24.1 Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? Yes [] No [X]
- 24.2 If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party.

Name of Third-Party	Is the Third-Party Agent a Related Party (Yes/No)

INVESTMENT

- 25.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 25.03)..... Yes [X] No []

GENERAL INTERROGATORIES

- 25.02 If no, give full and complete information, relating thereto
.....
- 25.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)
N/A
- 25.04 For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions. \$0
- 25.05 For the reporting entity's securities lending program, report amount of collateral for other programs. \$0
- 25.06 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? Yes [] No [] N/A [X]
- 25.07 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? Yes [] No [] N/A [X]
- 25.08 Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending? Yes [] No [] N/A [X]
- 25.09 For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:
- 25.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. \$0
- 25.092 Total book/adjusted carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2 \$0
- 25.093 Total payable for securities lending reported on the liability page. \$0
- 26.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03). Yes [X] No []
- 26.2 If yes, state the amount thereof at December 31 of the current year:
- 26.21 Subject to repurchase agreements \$0
- 26.22 Subject to reverse repurchase agreements \$0
- 26.23 Subject to dollar repurchase agreements \$0
- 26.24 Subject to reverse dollar repurchase agreements \$0
- 26.25 Placed under option agreements \$0
- 26.26 Letter stock or securities restricted as to sale -
excluding FHLB Capital Stock \$0
- 26.27 FHLB Capital Stock \$0
- 26.28 On deposit with states \$ 81,770,802
- 26.29 On deposit with other regulatory bodies \$0
- 26.30 Pledged as collateral - excluding collateral pledged to an FHLB \$0
- 26.31 Pledged as collateral to FHLB - including assets backing funding agreements \$0
- 26.32 Other \$0

26.3 For category (26.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount

- 27.1 Does the reporting entity have any hedging transactions reported on Schedule DB? Yes [] No [X]
- 27.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Yes [] No [] N/A [X]
If no, attach a description with this statement.

LINES 27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:

- 27.3 Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity? Yes [] No []
- 27.4 If the response to 27.3 is YES, does the reporting entity utilize:
- 27.41 Special accounting provision of SSAP No. 108 Yes [] No []
- 27.42 Permitted accounting practice Yes [] No []
- 27.43 Other accounting guidance Yes [] No []
- 27.5 By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: Yes [] No []
- The reporting entity has obtained explicit approval from the domiciliary state.
 - Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21.
 - Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount.
 - Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.
- 28.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity? Yes [] No [X]
- 28.2 If yes, state the amount thereof at December 31 of the current year. \$0
29. Excluding items in Schedule E - Part 3 - Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III - General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping Agreements of the NAIC Financial Condition Examiners Handbook?..... Yes [X] No []

29.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
State Street Bank and Trust Company	State Street Financial Center; One Lincoln Street; Boston, MA 02111-2900

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

GENERAL INTERROGATORIES

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?..... Yes [] No [X]

29.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1 Name of Firm or Individual	2 Affiliation
Derek S. Blunt as Senior Investment Officer	A.....

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's invested assets?..... Yes [] No [X]

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... Yes [] No [X]

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name of Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Management Agreement (IMA) Filed
N/A	Derek S. Blunt	N/A	Not registered	NO.....

30.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [] No [X]

30.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund's Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
	Statement (Admitted) Value	Fair Value	Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
31.1 Bonds	214,486,963	211,249,561	(3,237,402)
31.2 Preferred stocks	0	0	0
31.3 Totals	214,486,963	211,249,561	(3,237,402)

31.4 Describe the sources or methods utilized in determining the fair values:

Fair value of long term bonds and preferred stocks are determined based on quoted market prices when available, fair values using valuation methodologies based on available and observable market information or by using matrix pricing. If quoted market prices are not available, we determine fair value using broker quoted or an internal analysis of each investment's financial performance and cash flow projections. Short Term investments are carried at amortized cost which approximated fair value. The carrying value of cash equivalents approximated fair value.

32.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? Yes [] No [X]

32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source? Yes [] No []

32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:
.....

33.1 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? Yes [X] No []

33.2 If no, list exceptions:
.....

34. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:

- a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.
- b. Issuer or obligor is current on all contracted interest and principal payments.
- c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

Has the reporting entity self-designated 5GI securities? Yes [] No [X]

35. By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:

- a. The security was purchased prior to January 1, 2018.
- b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
- c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.
- d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.

Has the reporting entity self-designated PLGI securities? Yes [] No [X]

36. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:

- a. The shares were purchased prior to January 1, 2019.
- b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.
- c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.
- d. The fund only or predominantly holds bonds in its portfolio.
- e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.
- f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? Yes [] No [X]

37. By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:

- a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.
- b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.
- c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.
- d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments.

Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? Yes [X] No [] N/A []

GENERAL INTERROGATORIES

38.1 Does the reporting entity directly hold cryptocurrencies? Yes [] No [X]

38.2 If the response to 38.1 is yes, on what schedule are they reported?
.....

39.1 Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies? Yes [] No [X]

39.2 If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars?

39.21 Held directly Yes [] No []

39.22 Immediately converted to U.S. dollars Yes [] No []

39.3 If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.

1 Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums

OTHER

40.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? \$0

40.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

1 Name	2 Amount Paid
	0

41.1 Amount of payments for legal expenses, if any? \$177,079

41.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1 Name	2 Amount Paid
	0

42.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any? \$0

42.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers, or departments of government during the period covered by this statement.

1 Name	2 Amount Paid
	0

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force? Yes [] No [X]

1.2 If yes, indicate premium earned on U.S. business only. \$ 0

1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? \$ 0

1.31 Reason for excluding
.....

1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above \$ 0

1.5 Indicate total incurred claims on all Medicare Supplement Insurance. \$ 0

1.6 Individual policies: Most current three years:

1.61 Total premium earned \$ 0

1.62 Total incurred claims \$ 0

1.63 Number of covered lives 0

All years prior to most current three years:

1.64 Total premium earned \$ 0

1.65 Total incurred claims \$ 0

1.66 Number of covered lives 0

1.7 Group policies: Most current three years:

1.71 Total premium earned \$ 0

1.72 Total incurred claims \$ 0

1.73 Number of covered lives 0

All years prior to most current three years:

1.74 Total premium earned \$ 0

1.75 Total incurred claims \$ 0

1.76 Number of covered lives 0

2. Health Test:

	1 Current Year	2 Prior Year
2.1 Premium Numerator	511,246,083	527,855,573
2.2 Premium Denominator	511,246,083	527,855,573
2.3 Premium Ratio (2.1/2.2)	1.000	1.000
2.4 Reserve Numerator	85,663,092	81,199,638
2.5 Reserve Denominator	85,663,092	81,199,638
2.6 Reserve Ratio (2.4/2.5)	1.000	1.000

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits? Yes [] No [X]

3.2 If yes, give particulars:
.....

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? Yes [X] No []

4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Yes [] No [X]

5.1 Does the reporting entity have stop-loss reinsurance? Yes [] No [X]

5.2 If no, explain:
The Company does not have any stop loss agreements.

5.3 Maximum retained risk (see instructions)

5.31 Comprehensive Medical \$ 9,999,999

5.32 Medical Only \$ 0

5.33 Medicare Supplement \$ 0

5.34 Dental & Vision \$ 0

5.35 Other Limited Benefit Plan \$ 0

5.36 Other \$ 0

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:
Provider contracts contain hold harmless and continuity of coverage provisions. In addition, the Company maintains an insolvency protection agreement with an affiliate of the Company.

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis?..... Yes [X] No []

7.2 If no, give details
.....

8. Provide the following information regarding participating providers: 8.1 Number of providers at start of reporting year 72,489
8.2 Number of providers at end of reporting year 70,660

9.1 Does the reporting entity have business subject to premium rate guarantees? Yes [] No [X]

9.2 If yes, direct premium earned: 9.21 Business with rate guarantees between 15-36 months.. \$ 0
9.22 Business with rate guarantees over 36 months \$ 0

GENERAL INTERROGATORIES

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? Yes [X] No []

10.2 If yes:

10.21 Maximum amount payable bonuses.....\$7,756,391

10.22 Amount actually paid for year bonuses.....\$9,356,624

10.23 Maximum amount payable withholds.....\$0

10.24 Amount actually paid for year withholds.....\$0

11.1 Is the reporting entity organized as:

11.12 A Medical Group/Staff Model, Yes [] No [X]

11.13 An Individual Practice Association (IPA), or, Yes [] No [X]

11.14 A Mixed Model (combination of above)? Yes [] No [X]

11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements? Yes [X] No []

11.3 If yes, show the name of the state requiring such minimum capital and surplus. New Jersey

11.4 If yes, show the amount required. \$ 33,252,825

11.5 Is this amount included as part of a contingency reserve in stockholder's equity? Yes [] No [X]

11.6 If the amount is calculated, show the calculation
See Notes to Financial Statement - Note 21, Other Items, C., Other Disclosures.

12. List service areas in which reporting entity is licensed to operate:

1 Name of Service Area
The Company is licensed in all counties in the State of New Jersey.

13.1 Do you act as a custodian for health savings accounts? Yes [] No [X]

13.2 If yes, please provide the amount of custodial funds held as of the reporting date. \$0

13.3 Do you act as an administrator for health savings accounts? Yes [] No [X]

13.4 If yes, please provide the balance of funds administered as of the reporting date. \$0

14.1 Are any of the captive affiliates reported on Schedule S, Part 3, authorized reinsurers? Yes [] No [X] N/A []

14.2 If the answer to 14.1 is yes, please provide the following:

1 Company Name	2 NAIC Company Code	3 Domiciliary Jurisdiction	4 Reserve Credit	Assets Supporting Reserve Credit		
				5 Letters of Credit	6 Trust Agreements	7 Other
.....

15. Provide the following for individual ordinary life insurance* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):

15.1 Direct Premium Written \$0

15.2 Total Incurred Claims \$0

15.3 Number of Covered Lives 0

*Ordinary Life Insurance Includes
Term(whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary gurarantee)
Universal Life (with or without secondary gurarantee)
Variable Universal Life (with or without secondary gurarantee)

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? Yes [] No [X]

16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? Yes [] No [X]

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Aetna Health Inc. (a New Jersey corporation)

FIVE-YEAR HISTORICAL DATA

	1 2023	2 2022	3 2021	4 2020	5 2019
Balance Sheet (Pages 2 and 3)					
1. Total admitted assets (Page 2, Line 28)	250,804,209	239,334,416	235,452,558	271,143,941	263,206,656
2. Total liabilities (Page 3, Line 24)	103,609,756	100,203,236	103,564,548	124,428,032	140,477,775
3. Statutory minimum capital and surplus requirement	33,252,825	38,730,922	43,557,454	45,456,922	61,349,778
4. Total capital and surplus (Page 3, Line 33)	147,194,453	139,131,180	131,888,010	146,715,909	122,728,881
Income Statement (Page 4)					
5. Total revenues (Line 8)	510,730,241	528,489,322	589,527,173	689,658,163	739,252,990
6. Total medical and hospital expenses (Line 18)	423,029,754	456,219,379	520,450,336	559,664,774	695,700,989
7. Claims adjustment expenses (Line 20)	13,189,207	10,319,044	10,782,290	13,337,408	17,466,928
8. Total administrative expenses (Line 21)	56,977,367	55,505,102	55,996,339	86,440,458	79,889,968
9. Net underwriting gain (loss) (Line 24)	17,533,913	6,445,797	2,298,208	30,215,523	(53,804,895)
10. Net investment gain (loss) (Line 27)	5,726,319	4,779,382	6,044,623	6,089,449	8,710,160
11. Total other income (Lines 28 plus 29)	(4,076)	0	0	0	0
12. Net income or (loss) (Line 32)	19,090,138	9,978,729	9,005,688	25,526,774	(31,557,554)
Cash Flow (Page 6)					
13. Net cash from operations (Line 11)	11,764,622	26,510,745	398,063	45,412,872	(25,401,199)
Risk-Based Capital Analysis					
14. Total adjusted capital	147,194,453	139,131,180	131,888,010	146,715,909	122,728,881
15. Authorized control level risk-based capital	16,626,413	19,365,461	21,778,727	22,728,461	30,674,889
Enrollment (Exhibit 1)					
16. Total members at end of period (Column 5, Line 7)	32,344	38,506	44,257	56,669	67,494
17. Total members months (Column 6, Line 7)	400,793	475,116	554,040	702,119	810,778
Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Lines 18 plus Line 19)	82.8	86.3	88.3	81.2	94.1
20. Cost containment expenses	1.8	1.4	1.4	1.4	1.6
21. Other claims adjustment expenses	0.8	0.5	0.5	0.5	0.7
22. Total underwriting deductions (Line 23)	96.6	98.8	99.6	95.6	107.3
23. Total underwriting gain (loss) (Line 24)	3.4	1.2	0.4	4.4	(7.3)
Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 17, Col. 5)	58,519,162	57,889,215	62,170,789	57,409,350	58,781,195
25. Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	53,193,507	56,603,683	61,819,074	71,276,875	58,595,430
Investments In Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27. Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	0
28. Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	0
29. Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30. Affiliated mortgage loans on real estate	0	0	0	0	0
31. All other affiliated	0	0	0	0	0
32. Total of above Lines 26 to 31	0	0	0	0	0
33. Total investment in parent included in Lines 26 to 31 above	0	0	0	0	0

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors? Yes [] No []
 If no, please explain:

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

		1	Direct Business Only								
			2	3	4	5	6	7	8	9	10
States, etc.		Active Status (a)	Accident and Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Federal Employees Health Benefits Program Premiums	Life and Annuity Premiums & Other Considerations	Property/Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
1. Alabama	AL	N	0	0	0	0	0	0	0	0	0
2. Alaska	AK	N	0	0	0	0	0	0	0	0	0
3. Arizona	AZ	N	0	0	0	0	0	0	0	0	0
4. Arkansas	AR	N	0	0	0	0	0	0	0	0	0
5. California	CA	N	0	0	0	0	0	0	0	0	0
6. Colorado	CO	N	0	0	0	0	0	0	0	0	0
7. Connecticut	CT	N	0	0	0	0	0	0	0	0	0
8. Delaware	DE	N	0	0	0	0	0	0	0	0	0
9. District of Columbia	DC	N	0	0	0	0	0	0	0	0	0
10. Florida	FL	N	0	0	0	0	0	0	0	0	0
11. Georgia	GA	N	0	0	0	0	0	0	0	0	0
12. Hawaii	HI	N	0	0	0	0	0	0	0	0	0
13. Idaho	ID	N	0	0	0	0	0	0	0	0	0
14. Illinois	IL	N	0	0	0	0	0	0	0	0	0
15. Indiana	IN	N	0	0	0	0	0	0	0	0	0
16. Iowa	IA	N	0	0	0	0	0	0	0	0	0
17. Kansas	KS	N	0	0	0	0	0	0	0	0	0
18. Kentucky	KY	N	0	0	0	0	0	0	0	0	0
19. Louisiana	LA	N	0	0	0	0	0	0	0	0	0
20. Maine	ME	N	0	0	0	0	0	0	0	0	0
21. Maryland	MD	N	0	0	0	0	0	0	0	0	0
22. Massachusetts	MA	N	0	0	0	0	0	0	0	0	0
23. Michigan	MI	N	0	0	0	0	0	0	0	0	0
24. Minnesota	MN	N	0	0	0	0	0	0	0	0	0
25. Mississippi	MS	N	0	0	0	0	0	0	0	0	0
26. Missouri	MO	N	0	0	0	0	0	0	0	0	0
27. Montana	MT	N	0	0	0	0	0	0	0	0	0
28. Nebraska	NE	N	0	0	0	0	0	0	0	0	0
29. Nevada	NV	N	0	0	0	0	0	0	0	0	0
30. New Hampshire	NH	N	0	0	0	0	0	0	0	0	0
31. New Jersey	NJ	L	8,954,135	500,416,103	0	0	16,373,917	0	0	525,744,155	0
32. New Mexico	NM	N	0	0	0	0	0	0	0	0	0
33. New York	NY	N	0	0	0	0	0	0	0	0	0
34. North Carolina	NC	N	0	0	0	0	0	0	0	0	0
35. North Dakota	ND	N	0	0	0	0	0	0	0	0	0
36. Ohio	OH	N	0	0	0	0	0	0	0	0	0
37. Oklahoma	OK	N	0	0	0	0	0	0	0	0	0
38. Oregon	OR	N	0	0	0	0	0	0	0	0	0
39. Pennsylvania	PA	N	0	0	0	0	0	0	0	0	0
40. Rhode Island	RI	N	0	0	0	0	0	0	0	0	0
41. South Carolina	SC	N	0	0	0	0	0	0	0	0	0
42. South Dakota	SD	N	0	0	0	0	0	0	0	0	0
43. Tennessee	TN	N	0	0	0	0	0	0	0	0	0
44. Texas	TX	N	0	0	0	0	0	0	0	0	0
45. Utah	UT	N	0	0	0	0	0	0	0	0	0
46. Vermont	VT	N	0	0	0	0	0	0	0	0	0
47. Virginia	VA	N	0	0	0	0	0	0	0	0	0
48. Washington	WA	N	0	0	0	0	0	0	0	0	0
49. West Virginia	WV	N	0	0	0	0	0	0	0	0	0
50. Wisconsin	WI	N	0	0	0	0	0	0	0	0	0
51. Wyoming	WY	N	0	0	0	0	0	0	0	0	0
52. American Samoa	AS	N	0	0	0	0	0	0	0	0	0
53. Guam	GU	N	0	0	0	0	0	0	0	0	0
54. Puerto Rico	PR	N	0	0	0	0	0	0	0	0	0
55. U.S. Virgin Islands	VI	N	0	0	0	0	0	0	0	0	0
56. Northern Mariana Islands	MP	N	0	0	0	0	0	0	0	0	0
57. Canada	CAN	N	0	0	0	0	0	0	0	0	0
58. Aggregate Other Aliens	OT	XXX	0	0	0	0	0	0	0	0	0
59. Subtotal	XXX		8,954,135	500,416,103	0	0	16,373,917	0	0	525,744,155	0
60. Reporting Entity Contributions for Employee Benefit Plans	XXX		0	0	0	0	0	0	0	0	0
61. Totals (Direct Business)	XXX		8,954,135	500,416,103	0	0	16,373,917	0	0	525,744,155	0
DETAILS OF WRITE-INS											
58001.	XXX										
58002.	XXX										
58003.	XXX										
58998. Summary of remaining write-ins for Line 58 from overflow page	XXX		0	0	0	0	0	0	0	0	0
58999. Totals (Lines 58001 through 58003 plus 58998)(Line 58 above)	XXX		0	0	0	0	0	0	0	0	0


(a) Active Status Counts:

- 1. L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG..... 1
- 2. R - Registered - Non-domiciled RRGs..... 0
- 3. E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0
- 4. Q - Qualified - Qualified or accredited reinsurer..... 0
- 5. N - None of the above - Not allowed to write business in the state..... 56

(b) Explanation of basis of allocation by states, premiums by state, etc.
All premiums are written within the State of New Jersey.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



This organizational chart reflects the insurance entity reporting system and identifies the relationship between the ultimate parent and all member insurers. The ultimate controlling company is a Fortune 6 company with numerous subsidiaries, the majority of which do not interact with the insurance entities.

(1) Insurers/HMO's

Percentages are rounded to the nearest whole percent and based on ownership of voting rights.


Double borders indicate entity has subsidiaries shown on the same page.

Bold borders indicate entity has subsidiaries shown on a separate page.

*1 Coram Clinical Trials, Inc. is also 25% owned by Aetna Life Insurance Company

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



*1 PHPSNE Parent Corporation is also 45% owned by third parties.
 *2 CVS Cabot Holdings Inc. is also 99.72% owned by Coram Clinical Trials, Inc.
 *3 CVS Shaw Holdings Inc. is also 99.72% owned by Coram Clinical Trials, Inc.
 *4 Omnicare, LLC is also owned by CVS Cabot Holdings Inc and CVS Shaw Holdings Inc., each with 49.86% ownership.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



*1 PT. Aetna Global Benefits Indonesia is also 20% owned by Suhatsyah Rivai, Aetna's Nominee.
 *2 Aetna Global Benefits (Middle East) LLC is also 51% is owned by Euro Gulf LLC, Aetna's Nominee.


SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



*1 Owned via a nominee

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART




*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).

*2 Banner Health and Aetna Health Insurance Holding Company LLC is also 50% owned by Banner Health.

*3 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP


PART 1 - ORGANIZATIONAL CHART



* Aetna Capital Management, LLC is the managing member of Aetna Partners Diversified Fund, LLC ("APDF"). APDF is a fund of hedge funds and certain subsidiaries of CVS Health Group invest in this fund, which does not confer any managing or controlling ownership interests in APDF. Aetna Life Insurance Company is the largest investor in APDF and currently owns a majority of the non-managing member interests of APDF.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURANCE MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART



*1 Aetna ACO Holdings Inc. is owned by Aetna Life Insurance Company (302 shares); Aetna Health Inc. (PA) (198 shares); and Aetna Health Holdings, LLC (1 share).

*2 Banner Health and Aetna Health Insurance Holding Company LLC is also 50% owned by Banner Health.

*3 Allina Health and Aetna Insurance Holding Company LLC is also 50% owned by Allina Health System.

*4 Coram Clinical Trials, Inc. is also 75% owned by CVS Pharmacy, Inc.

*5 CVS Cabot Holdings Inc. is also .28% owned by Aetna Inc.

*6 CVS Shaw Holdings Inc. is also .28% owned by Aetna Inc.

*7 Remaining .28% owned by Aetna Inc. CVS Cabot Holdings Inc. and CVS Shaw Holdings Inc. each owning 49.86%.

*8 CVS Health Venture Fund, LP is also 0.1% owned by CVS Helath Ventures Fund GP, LLC

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Underwriting and Investment Exhibit Part 3 Line 25

	Claim Adjustment Expenses		3 General Administrative Expenses	4 Investment Expenses	5 Total
	1 Cost Containment Expenses	2 Other Claim Adjustment Expenses			
2504. Interest expense	0	140,883	232,315	0	373,198
2505. Admin Fees - Reinsurance	0	0	13,357	0	13,357
2597. Summary of remaining write-ins for Line 25 from overflow page	0	140,883	245,672	0	386,555